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INTRODUCTION 

Chapter 1 
THE HUMAN PLACENTA AND ITS TRANSPORT FUNCTION 
- emphasis on mechanisms of drug transfer -
Eric M. van der Aa, Jenny HJ. Copius Peereboom-Stegeman', Jan Noordhoek8, 
Frank W.J. Gribnau and Frans G.M. Rüssel 
Departments of Pharmacology and Toxicology5, University of Nijmegen, P.O. Box 
9101, 6500 HB Nijmegen, the Netherlands 
INTRODUCTION 
The placenta is an important organ for optimal growth and development of 
embryo and fetus during pregnancy. It combines functions performed by separate 
organs in adult life. Absorption of nutrients and excretion of waste products are 
major functions of the placenta, which in neonates are performed mainly by 
intestine and kidney, respectively. For gas transfer, after birth performed by the 
lungs, the fetus is also dependent on the placenta. Furthermore, hormone synthesis 
by the placenta, as an endocrine gland and metabolic activity, mainly performed by 
the liver in later life, are of great importance. The first to maintain the state of 
pregnancy and the latter to assure energy supply for continuous synthesis and 
(active) transport processes. (1,2). The complex function of the placenta justifies the 
concept that transport systems must be present to assure fetal nutrition and 
excretion. 
In this review literature data are summarized concerning human placental 
transport mechanisms with special reference to drugs. Active trans-placental 
transport processes, placental metabolism, pH differences between maternal and 
fetal blood and differential maternal/fetal protein binding might influence fetal drug 
exposure and hence fetal growth and development (3). For a better understanding of 
the placenta as a transport organ we start with an overview of placental 
characteristics, which are important for the trans-placental transfer of compounds in 
general. 
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THE PLACENTA AS A TRANSPORT ORGAN 
The placenta in history 
The importance of the afterbirth was already clearly recognized by the 
ancient Egyptians. The 'royal placenta' was carried in ceremonial processions right 
before the pharaoh, indicating the special value given to this organ. The 'placenta', 
important for good health of the pharaoh and his kingdom, was believed to be the 
home of the external soul (4,5) 
Although the importance of this organ was known far before our era, the 
term placenta firstly appeared in 1559 A.D. in 'DE RE ANATOMICA' by Realdus 
Columbus (1516-1559). However, it lasted until the period of William and John 
Hunter (1718-1793) before the relationship of the unit mother-placenta-fetus was 
understood. The discovery of the circulation of blood and consequently the 
explanation of the fetal circulation by William Harvey (1578-1657) and the 
demonstration by John Mayow (1643-1679) that particles were transferred from 
maternal to fetal circulation, was of great help to the Hunters for their description of 
the maternal-placental-fetal axis. In the first half of the 20th century several 
schemes were proposed to describe and classify the different mammalian placentae 
of different species, in an attempt to correlate placental function to placental 
structure (6,7). Only the classification of Grosser (8), based on the number of tissue 
layers between the maternal and fetal circulation is still useful to explain several 
transport characteristics across the placenta. His scheme, however, implies that the 
placenta is purely a passive filter and does not take into account the possible active 
transport mechanisms, as described for instance for amino acids in the late 1940's 
(9). Factors like placental shape and vessel geometry are also ignored (10). The 
general idea that the structure of the placenta is of importance for its function, 
however, did stand the test of time. 
Placental anatomy in relation to its transport function 
Anatomy of the human term placenta 
The human placenta is a discoid organ with a diameter of approximately 20 cm, a 
thickness of about 3 cm and a weight of approximately 500 grams at term. The 
placenta is formed by the chorion frondosum (fetal tissue) and decidua basalis 
(maternal tissue). Decidua septa formed by the decidua basalis divide the placenta 
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into several compartments called cotyledons. Such a cotyledon can be considered as 
a functional unit within the placenta. It contains a villus tree, in which the maternal 
and fetal circulation are separated by means of the placental barrier. This barrier 
consists of the endothelium of the fetal capillaries and the trophoblast, containing 
the villus stroma, the cytotrophoblast and the syncytiotrophoblast. As pregnancy 
proceeds the thickness of the barrier reduces due to the partial disappearance of the 
cytotrophoblast layer. The syncytiotrophoblast is bordered at the maternal side by 
the syncytial microvillous membrane, which contacts directly to the maternal blood 
in the intervillous spaces. The basal membrane covers the syncytiotrophoblast at the 
fetal side. Transport across the placenta is greatly regulated by these two 
membranes. Therefore the trophoblast can be considered as a polar epithelium, as is 
also present in other organs like kidney, intestine, blood-brain barrier, and through 
which almost all materials must pass in their transfer from mother to fetus and vice 
versa. A diagrammatic representation of the human placenta is given in Figure 1. 
Figure 1. The human placenta with its arterial and venous supply. Adapted from Bourget et al. 
(11) with permission. 
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Species differences in placental anatomy 
As mentioned before, Grosser's classification is still useful for the 
explanation of structural-functional relationships of the placenta. Table 1 shows the 
type of placentae and the number of layers between maternal and fetal blood. 
Placentae having maternal epi- or endothelia are classified as epithelio- or 
endotheliochorial. Placentae in which maternal blood directly contacts the 
trophoblast are called haemochorial, further subdivided according to the number of 
trophoblastic layers between maternal and fetal blood. Not only factors as 
mentioned in the classification of Grosser indicate the differences in placental 
structure between species, the shape of the mature placenta also differs. For humans 
in the early stage of pregnancy the placenta has a diffuse shape, viz. villi cover the 
entire surface, whereas the human placenta in late gestation is discoid, characterized 
by formation of the villi in a circulate plate with defined margins. In ruminants, like 
sheep and cow for instance, the placenta, has villi restricted to defined regions of 
the uterus (1). 
Assuming that such differences in placental structure must have their 
influence on placental transfer properties, data from animal studies can not be 
completely predictive for the situation in the human placenta. 
Table 1. Grosser's classification. 
placental type 
epitheliochorial 
endotheliochorial 
haemochorial mono 
di 
tri 
mb mee 
+ 
+ 
-
-
-
met 
+ 
-
-
-
-
tissue layers 
me is tr 
+ + 
+ 
+ 
++ 
+++ 
fct 
+ 
+ 
+ 
+ 
+ 
fee 
+ 
+ 
+ 
+ 
+ 
fb 
species 
sheep, pig 
dog, cat 
human, guinea pig 
rabbit 
rat, mouse 
Modified from Page (1), the Physiology of the Human Placenta, pp 13. +: number of cell layers; 
fb: fetal blood; fee: fetal capillary endothelium; fct: fetal connective tissue; is: intervillous space; 
mb: maternal blood; mce: maternal capillary endothelium; met: maternal connective tissue; me: 
maternal epithelium; tr: trophoblast. 
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Placental anatomy and permeability 
The permeability of the (human) placenta is comparable to other lipid 
membrane containing structures. Lipid soluble substances will freely cross the 
membrane barrier and lipid insoluble compounds will encounter difficulties in 
crossing the membranes. 
Lipophilic compounds will cross the placenta depending on their molecular 
size, degree of ionization, protein binding and lipid solubility. Molecules with a 
molecular weight up to 600 Da, non-ionized and lipid soluble will show unimpeded 
diffusion. The rate of transfer of such compounds is not dependent on the 
diffusibility across the membranes, but depends on factors that regulate maternal 
and fetal blood flows. This kind of transfer is therefore called 'flow-limited'. In this 
case the rate of passage across the placental membranes is identical to the delivery-
rate by the blood stream (1). 
In contrast, polar, ionized, hydrophilic compounds will cross the placenta 
more slowly. The rate of membrane transfer is slower than the rate of delivery by 
the blood stream. This process is called 'membrane limited' transfer, and the 
constitution of the membranes determines the rate of transfer. 
Especially for hydrophilic molecules, large differences among species have 
been shown for placental permeability (12). The permeability of human placenta is 
considerably higher than sheep placenta (13) and comparable to guinea-pig placenta 
(14). In the sheep there is no significant diffusional flux for hydrophilic compounds 
with a molecular weight up to 400 Da. However, in the guinea-pig there is no 
restriction in diffusion for molecules with a weight up to 5000 Da. Permeability 
data of the human placenta are mainly derived from in vitro experiments. In the 
perfused human placental cotyledon a close correlation was observed between 
placental permeability and molecular weight for hydrophilic compounds (15). More 
recently, permeability of the human placenta determined in vivo, at the time of 
Caesarian section, showed a reasonable agreement between in vitro and in vivo data 
(12,16-18). In human placental membrane vesicles it was shown that the 
permeability of the basal membrane was substantially higher than of the syncytial 
microvillous membrane for hydrophilic non-electrolytes (19). 
The observed species differences in placental permeability are predominantly 
the reflection of structural differences. The high leakyness of the human and guinea-
pig placenta, as compared with the sheep placenta, is due to the fact that the former 
two have a haemochorial type of placenta, whereas the latter has a epitheliochorial 
type of placenta, in which more tissue layers separate the maternal and fetal 
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bloodstreams. There is physiological evidence for paracellular pathways in the 
human placenta as an explanation for the high leakyness (20). No unequivocal 
morphological proof for water filled membrane channels has yet been given. By 
electron microscopy, vesicular and tubular structures have been shown in the 
guinea-pig placenta, but there is no evidence for such structures in the human 
placenta (21). Thus, in the haemochorial placenta the trophoblast and the 
endothelium are responsible for the diffusional resistance to hydrophilic compounds, 
such that the trophoblastic components determine the overall diffusion barrier and 
intercellular spaces in the endothelium restrict the diffusion of larger molecules 
(22). A model has been proposed by Stulc (20) in which the trophoblast contains a 
limited number of wide openings yielding a low permeability and the second, 
endothelial, layer possesses a high density of narrow pores, resulting in a high 
permeability. 
Placental ageing and permeability 
As pregnancy proceeds placental structure changes. These changes are often 
regarded as ageing of the placenta, but they can also be viewed (23) as a maturation 
mechanism. The exponential progress in fetal weight during gestation is not 
accompanied by a proportional increase in placental weight. After 16 weeks of 
pregnancy, a reduction in thickness of the barrier between maternal and fetal 
circulation occurs, due to the partial disappearance of the cytotrophoblast layer. The 
observable changes in villus structure must be explained as an enlargement of 
exchange area. This will result in a higher permeability and more efficient exchange 
of nutrients, necessary for the increased demands of the developing fetus. In early 
pregnancy the distance between both circulations is about 10 micron and decreases 
to about 2 micron in late gestation (23,24). 
Thus, due to changes in the placental barrier, compound transfer in term 
placenta is not completely comparable to that in preterm placenta. However, 
placental structure differences between species are assumed to be of greater 
influence on transport characteristics than the ageing phenomena and therefore 
human data are to be preferred. 
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HUMAN PLACENTAL TRANSPORT MECHANISMS 
Drug use during pregnancy 
In an overview of epidemiological drug utilization studies it was shown that 
a considerable amount of drugs was used during pregnancy. Analgesics, antiemetics, 
antibiotics, tranquilizers, antihistaminics and diuretics were the most widely taken 
classes of drags (25). In a Dutch investigation of drag use during pregnancy at least 
one prescription was received by 86% of the mothers, regarding all three trimesters 
of pregnancy. As pregnancy proceeds the amount of prescribed drugs generally 
decreased (except for gastro-intestinals and vitamins), possibly due to the awareness 
of the mother and physician of the potential risks to the fetus of maternal drag 
utilization (26). However, in some cases, for instance maternal epilepsy or diabetes, 
the mother is continuously exposed to drags during pregnancy. The perinatal use of 
uterine smooth muscle relaxants (tocolytics like ritodrine and calcium channel 
blockers) and uterine stimulating drags (oxytocin and Prostaglandines) to inhibit or 
stimulate the beginning of labour, is another form of obligatory maternal drug use 
before the end of pregnancy. Furthermore, fetal therapy via maternal drag 
administration is expected to be employed increasingly. All these factors underline 
the importance of a good insight into the mechanisms that determine placental drug 
transfer and fetal plasma concentrations after maternal drag administration. 
Placental transport mechanisms 
1. As mentioned before, most (pharmacologically active) compounds cross the 
human placenta by simple diffusion. Transfer in this case is without the use 
of energy, dependent on the concentration gradient between maternal and 
fetal blood, the surface area and thickness of the membrane barrier as 
governed by Fick's law. Placental blood-flow, pH of maternal and fetal 
blood, physico-chemical characteristics of the compounds and protein binding 
further determine the capability of crossing the placental membranes. 
2. In case of facilitated diffusion placental transfer is carrier mediated, but not 
dependent on energy. Transfer occurs down the concentration gradient, is 
inhibitable by structural analogs and is saturable. Especially drags structurally 
related to endogenous compounds are assumed to be transported by a 
facilitated diffusion mechanism. 
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3. Compound transfer by an active transport mechanism occurs against an 
electrochemical or concentration gradient, requiring energy. Transport is 
carrier mediated, saturable and there is competition between related 
molecules. In case of nutrient transport in fetal direction and probably fetal 
excretion of xenobiotics into the maternal circulation, placental active 
transport mechanisms may be involved. 
4. A less important route of placental drug transfer can be through pinocytosis. 
The compound is invaginated into the 'cell membranes' after which it is 
transferred to the opposite site. 
During the past 20 years several transport systems have been identified in the 
human placenta. Mostly transport systems for endogenous compounds or nutrients 
are concerned. A summary of the most important transport systems for such 
substances, studied in isolated placental membrane vesicles, is given in Table 2. 
For xenobiotic compounds human placental transport mechanisms are far less 
well documented. In a few studies the inhibitory effects of certain drugs on 
transporters for endogenous compounds were investigated: cyclosporine inhibits 
taurine transport (27), salicylate inhibits sulphate transport (28); loperamide, 
Clonidine and Cimetidine inhibit the Na7H+-exchanger (29-31) and 
amiloride(analogs) (32) and Clonidine and Imipramine (33) inhibit the 
guanidine/proton antiporter. 
Human placental transfer of drugs is often studied during labour by sampling 
maternal and umbilical cord blood following maternal bolus drug administration. 
This technique, however, suffers from several disadvantages such as: dependency of 
fetal/maternal serum concentration ratios on the time between drug administration 
and serum sampling, lack of comparison with a proper reference compound or 
difficulties in evaluating the influence of placental metabolism on drug transfer. For 
data concerning in vivo fetal-maternal plasma concentration ratio's excellent reviews 
have been written on placental drug transfer to which we refer to (34-37). 
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Table 2. Transport systems for endogenous compounds in the huma 
Compound 
Anorganic anions 
so,2-
P043 
CI 
Organic anions 
lactate 
succinate 
Anorganic cations 
Na+ 
H+ 
Ca2+ 
Organic cations 
guanidine 
choline 
Miscellaneous 
amino acids 
glucose 
dipeptides 
bile acids 
Mechanism 
anion exchange 
sodium-coupled cotransport 
anion exchange 
conductive pathway 
proton-coupled symport 
sodium-coupled cotransport 
proton exchange 
amiloride sensitive channel 
ATP-dependent 
ATP-dependent 
proton exchange 
proton-coupled antiport 
conductive pathway 
sodium-coupled cotransport 
facilitated diffusion 
facilitated diffusion 
facilitated diffusion 
anion exchange 
Localisation 
SMM, 
SMM 
SMM 
SMM 
SMM 
SMM 
SMM, 
SMM 
SMM 
BM 
SMM 
SMM 
SMM 
SMM, 
BM 
SMM, 
SMM 
SMM, 
BM 
BM 
BM 
BM 
BM 
in placenta. 
Reference 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
33 
49,50 
51 
51 
52,53 
54 
55,56 
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The body of data on mechanisms underlying explicitly human placental drug 
transport is relatively small. This is in contrast to the amount of information 
regarding other epithelial organs, like kidney, intestine and liver. The importance of 
mechanistic studies is indicated by recent results concluding that, although the 
anatomical structure differs, the placental microvillous membrane has much in 
common with the basolateral membrane rather than the brush-border membrane of 
other well characterized transporting epithelia (57), that the human placenta can 
express pharmacologically distinguishable types of transporters localized at different 
membranes (58) and that placental transport systems can be pharmacologically 
distinct from similar transporters in other tissues (59). 
Techniques for in vitro perfusion of placental tissue and isolation of placental 
membrane vesicles were introduced in the seventies. They have been playing an 
important role in overtaking the relative arrearage in knowledge, as is shown by the 
expanding literature during the last decade on placental drug transport mechanisms. 
The dually perfused isolated human placental cotyledon, introduced by Schneider et 
al. (60), enables the study of mechanisms underlying for instance low umbilical 
cord/maternal serum concentration ratios. With this method placental drug transfer 
can be evaluated in relation to flow-, and membrane-limited reference compounds, 
such as antipyrine and inulin. Furthermore, the influence of placental metabolism, 
the preferential direction of transport and the presence of overall active transport 
can be evaluated. Isolated membrane vesicles of human (term) placenta, can 
contribute further to the elucidation of driving forces, inhibitory susceptibility, 
specificity and saturability of membrane bound transport systems for exogenous 
compounds or transport systems primarily present for endogenous compounds, 
which have also affinity for xenobiotics (61). 
In this chapter we summarized literature data on the mechanisms of human 
placental drug transport studied in the isolated perfused placental cotyledon, 
placental membrane vesicles or trophoblastic cell cultures. Table 3 summarizes the 
present knowledge on transport characteristics of groups of drugs, clinically relevant 
during pregnancy or labour, further subdivided into individual agents. For 
abbreviations used in Table 3 see page 22. 
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Table 3 shows that for almost all drugs the transfer rates did not exceed the 
transfer rate of the diffusion markers antipyrine (flow-dependent diffusion) and L-
glucose (simple diffusion), viz. CI and TI < 1. A CI greater than unity was 
observed only for the antiepileptic drag carbamazepine due to its higher 
lipophilicity than antipyrine (80) and for the anti-malaria drug mefloquine (123), 
which probably resulted from its biexponential kinetic behaviour; a rapid placental 
uptake followed by slower transfer into the fetal circulation. Transplacental transfer 
of azidothymidine (84) was faster than the diffusion of L-glucose, due to its greater 
lipophilicity. However, azidothymidine did not equilibrate as fast as antipyrine, 
probably because of extensive placental metabolism. 
Transfer fractions and percentages of transfer in maternal to fetal direction 
varied from almost zero to 100 %. In general, this variability was mainly correlated 
with the physico-chemical characteristics of the compounds studied, such as 
lipophilicity, degree of ionisation or degree of protein binding. For instance, the 
more lipid soluble ß-antagonists timolol, labetolol and propranolol showed a 4-times 
higher steady-state diffusion rate than the more hydrophilic congeners atenolol and 
Celiprolol (95). Heparin showed an extremely low trans-placental transfer, due to its 
high molecular weight (15000 Da) and its negative charge (121). Other factors of 
impaired trans-placental transfer are significant tissue binding, as was the case for 
aspirin (74), theophyline (112,113) and digoxine (100), or significant placental 
metabolism, which was found for azidothymidine (84,85), dexamethasone 
(106,109), Prednisolon (107-109) and carbacyclin (125,126). These compounds are 
structural analogs of endogenous compounds and appeared to be substrates for 
placental metabolic systems. This was also seen for p-aminobenzoic acid, which 
was acetylated by the human placenta, resulting in a low placental transfer of only 
16 % (129). All major drug metabolic pathways present in other tissues are also 
found in the human placenta, mostly to a lesser extent but they can be quite 
efficient (130). The implications of these systems for placental drug tansfer, 
however, need further investigation. 
In perfusion studies overall placental drug transfer appeared to occur by 
simple diffusion. However, in placental membrane vesicles facilitated diffusion has 
been found for cephalosporins (67), gancyclovir (92) and corticosterone (104,105). 
It is assumed that these drugs are transported by systems primarily present for 
endogenous dipeptides, nucleosides and hormones, respectively. For 
pharmacologically active compounds, such as dopamine (131), noradrenaline (132) 
and serotonine (133), sodium-dependent active transport systems have been found in 
human placental SMMV. Although several drugs were able to inhibit transport of 
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these endogenous drugs (134,135), the implications of the presence of these systems 
and their transport capacity for placental transfer of for instance antipsychotics, 
antidepressants and anti-parkinson drugs have not been investigated yet. 
For most vitamins active transport systems have been found in the human 
placenta. Pharmacologically important vitamins, such as retinol and folate, appeared 
to be exceptions. Retinol was transferred across the human placenta with a transfer 
index of 0.73 (for comparison, the actively transported vitamins thiamin and 
riboflavin had transfer indices of 2.1 and 3.4), indicating transport by simple 
diffusion (136). High affinity binding sites for folate were found (137) in human 
placental microvilli, however, their role in placental folate transport is not fully 
elucidated. Preliminary experiments showed that membrane binding accounted for 
the main part of uptake into microvillous membrane vesicles (138). 
Transport systems for sex steroids, another group of endogenous compounds 
with pharmacological implications, have not been described until now. Possibly, the 
membrane bound P-glycoprotein (multi-drug resistance protein), which is 
abundantly present in the human placenta, although its exact membrane localization 
has yet to be determined, plays a role in placental hormone transport. Additionally, 
preliminary experiments have suggested that this protein may also act as а СГ-
channel, establishing and maintaining the observed trans-placental (fetal to maternal) 
chloride gradient (139). 
In summary, overall human placental drug transport rarely exceeds the 
transfer of flow-dependent and membrane-limited marker compounds. Interestingly, 
relatively often placental drug transfer appeared to be much smaller, indicating 
impaired trans-placental transport, depending on the physico-chemical characteristics 
of the drug or placental factors such as tissue binding or metabolism. Although in 
perfusion studies overall human placental drug transport occurred by simple 
diffusion, at the membrane level several drug transport systems have been found, 
mainly for drugs structurally related to endogenous compounds. 
SCOPE OF THIS THESIS 
The aim of the studies described in this thesis was a systematic approach to 
the unanswered questions concerning placental drug transport mechanisms. In 
contrast to other tissues, such as kidney, liver and intestine, the characteristics of 
classic transport systems for anionic and cationic drugs have not been investigated 
in the human placenta. In the kidney, the basolateral membrane of the proximal 
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tubular cell posesses a tertiary active transport system for anionic drugs. Ibis 
system mediates efficient tubular uptake of these drugs from the blood, resulting in 
the establishment of a concentration gradient, which acts as a driving force for 
urinary excretion across the brush-border membrane by facilitated diffusion (140). 
For cationic drugs, tubular uptake across the basolateral membrane occurs by 
(facilitated) diffusion, after which active urinary excretion is achieved by an organic 
cation-proton antiporter in the brush-border membrane (140). In this thesis we tried 
to elucidate whether comparable transport mechanisms are present in the human 
placenta, assuming that the placenta may play a role in the excretion of drugs from 
the fetal circulation. Drugs can reach this compartment by diffusion due to the 
trans-placental concentration gradient formed after maternal drug administration. It 
can be also speculated that high and possibly toxic fetal plasma concentrations are 
achieved when such transport mechanisms accumulate maternally taken drugs into 
the placenta, forming a driving force for transport into the fetal circulation by 
(facilitated) diffusion. Furthermore, we tried to characterize quantitatively the 
interaction of various anionic and cationic drugs with transport systems for nutrients 
such as amino acids and the cation choline. For all these mechanistic studies, 
isolated syncytial microvillous membrane vesicles were used. This technique is very 
well suited for the elucidation of transport driving forces, susceptibility to inhibition 
by foreign compounds and saturability of transport systems. 
In the second part of this thesis we describe the use of a perfusion system of 
the isolated human placental cotyledon. By mimicking the maternal and fetal blood 
circulations, contacting this functional unit, factors underlying the observed low 
trans-placental transfer of the antibiotic spiramycin were investigated. 
By studying drug transport and drug-nutrient interactions in the human 
placenta, we tried to contribute to the insight into factors determining placental and 
fetal exposure to drugs after maternal administration. 
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Summary 
The initial step in placental uptake of nutrients occurs across the syncytial 
microvillous membrane of the trophoblast. This study was designed to isolate 
syncytial microvillous membrane vesicles (SMMV) of human term placenta, to 
validate their purity and viability and to investigate the interaction of several 
commonly used drugs with the transport of two essential nutrients: alanine and 
choline. SMMV were isolated according to an established procedure, but instead of 
homogenization the initial preparation step was replaced by mincing of placental 
tissue followed by gently stirring to loosen the microvilli. These modifications 
doubled the protein recovery and increased the enrichment in alkaline phosphatase, 
whereas no substantial contamination with basal membranes nor interfering 
subcellular organelles was found. The functional viability of the vesicles was 
evaluated through the transport of alanine. In accordance with literature uptake was 
sodium-dependent, inhibitable by structural analogues and saturable. A number of 
cationic drugs were able to inhibit choline uptake, whereas no effect on alanine 
transport was observed. Anionic drugs, drugs of abuse and catecholamines did not 
interfere with alanine transport either. In conclusion, our isolated SMMV provide a 
suitable tool for screening drug-nutrient interactions at the level of membrane 
transport. In view of the very low susceptibility of the alanine transporter to drug 
inhibition and the relatively high drug concentrations necessary to inhibit choline 
transport, it seems unlikely that clinically important drug interactions may occur 
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with these nutrients. 
Introduction 
In the human haemochorial placenta the trophoblast forms a true syncytium 
without intercellular spaces. This polarized epithelium separates maternal and fetal 
circulation by means of the syncytial microvillous membrane (SMM) facing the 
maternal circulation and the basal membrane (BM) facing the fetal circulation. Fetal 
supply of nutrients and excretion of waste products across the placenta is mediated 
by these membranes forming, together with a core of connective tissue, the 
functional unit of the human placenta, called chorionic villus or cotyledon (Page, 
1993). 
During the past 20 years several procedures have been described for the 
isolation of membranes from human term placenta. Isolation of SMM was 
introduced by Smith et al. (1974), who separated microvilli from their 
syncytiotrophoblastic surface by isotonic agitation. Nowadays, widely used 
modifications of this method involve homogenization or mincing of placental tissue 
followed by differential centrifugation, with (Booth et al., 1980; Glazier et al., 1988; 
Illsley et al., 1990) or without (Boyd and Lund, 1981) Mg2+-aggregation of non-
microvillous membranes. Isolation procedures for syncytial basal membranes (BM), 
however, are less often described. The main reason for this is the poor accessibility 
of these membranes in the syncytial structure of the trophoblast. A method 
relatively often referred to in literature involves sonication, hypotonic lysis and 
EDTA incubation to detach separate membranes from the connective tissue, 
followed by discontinuous Ficoll-gradient centrifugation (Kelley et al., 1983) or 
differential centrifugation (Hoeltzli et al., 1990). Membrane vesicles are a pre-
eminent tool to investigate mechanisms of transport and drug interactions on 
nutrient transporters, independently of other cell types or placental metabolism. 
Fetal growth depends highly on placental transport of nutrients from the 
maternal to the fetal circulation. The initial step in placental transfer involves active 
uptake across the SMM into the trophoblast. The neutral amino acid alanine is the 
most abundant amino acid in maternal circulation (Philipps et al., 1978) and 
essential for fetal protein synthesis or as energy source for placental or fetal 
metabolism. The quaternary ammonium compound choline must be transported 
from maternal circulation into the trophoblast, because the placenta is unable to 
synthesize choline (Welsch, 1978). Obviously, interaction with the transfer of these 
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nutrients may impair fetal growth. 
Transfer of alanine across the SMM occurs predominantly via the sodium-
dependent system A. The system is responsible for the accumulation of alanine 
from the maternal circulation into the trophoblast. The gradient established enables 
(facilitated) diffusion of this amino acid into the fetal circulation, resulting in a 
higher fetal than maternal alanine concentration (Yudilevich and Sweiry, 1985). 
Since several drugs, like ouabain and digoxin, can interfere with Na7K+ ATP-ase, 
an enzyme essential for maintaining the transmembrane sodium-gradient, an 
inhibitory effect on alanine transport can be assumed (Kihlstrom and Kihlstrom, 
1981). Drugs may also interact directly with the human placental alanine transporter 
as was shown by Dicke et al. (1993) for S(-) cocaine in human microvillous 
membrane vesicles. Barnwell and Rama Sastry (1983) found reduced active uptake 
of the system Α-dependent amino acid AIB in the presence of high concentrations 
of cocaine, nicotine or morphine in human placental villi, but the type of inhibition 
could not be attributed to competition with the amino acid at the transport site. In a 
human cotyledon perfusion system transfer of AIB was not impaired by ethanol 
(Schenker et al., 1989a) or nicotine and a combination of nicotine and ethanol 
(Schenker et al., 1989b). Furthermore, acetaldehyde did not inhibit sodium-
dependent alanine uptake into SMMV (Asai et al., 1984). Acetylsalicylic acid has 
been shown to inhibit alanine transfer into the trophoblast in a guinea pig placenta 
perfusion system, but this was assumed to be an indirect effect, due to an influence 
on the uterus muscle by-pass flow (Rybakowski et al., 1993). The metabolic 
inhibitors dinitrophenol and iodoacetate did reduce alanine transfer in sheep 
placenta (Sepulveda and Wooding, 1984). The local anaesthetic lidocaine and the 
anti-cholinergics scopolamine and atropine did interact with AIB uptake in a 
nonspecific nature (Fant and Harbison, 1981). Inhibitors of choline-acetyltransferase 
were able to inhibit AIB uptake in placental villi. These results suggest that neutral 
amino acid transport is linked to the cholinergic system (Rowell and Rama Sastry, 
1981). 
The mechanisms of placental transport of choline, a precursor in the 
cholinergic system and phospholipid synthesis were recently investigated in our 
laboratory. Uptake into SMMV was found to be membrane potential-dependent and 
saturable with a K,
n
 of 550 uM (van der Aa et al., 1994b). 
Hardly any information is available on the mechanisms of drug interactions 
with nutrient transporters. We designed this study to isolate SMMV, validate their 
fuctional viability, and investigate the potential of various commonly used drugs to 
interact with membrane transport of alanine and choline. 
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Materials and Methods 
Isolation of membrane vesicles 
SMMV were isolated essentially according to method 3 as described by 
Glazier, Jones and Sibley (1988), based on the method reported by Booth and 
Kenney (1974) for rabbit kidney brush-border membrane vesicles. However, we 
introduced some modifications in order to improve the isolation performance. 
Human term placentas from uncomplicated pregnancies were obtained within 
15 min after vaginal or ceasarian delivery and brought into 0.9% NaCl (4°C). All 
subsequent steps were performed at 4°C. After removing the cord, amniochorion 
and decidua, placental tissue was cut from the maternal side and washed three times 
in 0.9% NaCl. The tissue was minced in a Waring blender in 300 mM Mannitol, 10 
mM Hepes-Tris, pH=7.4 and 1 mM MgSO< (MHT buffer). The mince was stirred 
for 30 min to loosen the microvilli and filtered through 4 layers of woven cotton 
gauze. A sample of this starting mince was taken for enzyme analysis. MgCl2 was 
added to the filtrate to a final concentration of 10 mM and the filtrate was stirred 
for 15 min. It was centrifuged at 2200*G for 10 min in an Heraeus sepatech 
Minifuge RF (Kalkberg, Germany). The pellet was discarded and the supernatant 
was centrifuged at 23500*G for 40 min in а ГЕС B-60 ultracentrifuge (Daiment 
Div., Needham, Massechuttes). G-forces were appointed to the bottom of the tube. 
The pellet from this run was suspended in MHT buffer with a 19G and 25G syringe 
needle (5 strokes). This homogenate was again exposed to 10 mM MgCl2. After 
repeated differential centrifugation, syncytial microvillous membrane vesicles were 
obtained and suspended with a 25G syringe needle (10 strokes) in a desired 
intravesicular buffer, frozen in liquid nitrogen and stored at -80°C for four weeks at 
the maximum. 
BMV were isolated from human term placenta according to Hoeltzli et al. 
(1990) for comparison of the Ca2+ uptake characteristics into SMMV and BMV. 
Briefly, tissue was minced in a warring blender and sonicated for 10 sec in portions 
of 30g/100ml 50 mM Tris-HCl buffer, pH=7.4. Subsequently, to free basal 
membranes from connective tissue, the mince was incubated for 30 min in 
hypotonic 5 mM Tris-HCl buffer, pH=7.4, followed by incubation for 30 min at 
room temperature (all other steps were performed at 4 °C) in 50 mM Tris-HCl, 250 
mM sucrose and 10 mM EDTA buffer, pH=7.4 and resonication for 20 sec. Basal 
membranes were purified by Mg2+-aggregation and differential centrifugation, frozen 
in liquid nitrogen and stored at -80 °C. 
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Analytical methods 
The activity of marker enzymes was analyzed according to previously 
described methods in MQ and SMMV: alkaline phosphatase for SMM (Mircheff and 
Wright, 1976), Na7K+ ATP-ase for BM (Schoot et al. 1977), succinate 
dehydrogenase for mitochondria (Pennington, 1961) and NADPH cytochrome-C-
reductase for smooth endoplasmatic reticulum (Omura and Takesue, 1970). Protein 
was assayed with a coomassie blue kit (Biorad, München, Germany) with bovine 
serum albumin as standard. 
Uptake of [3H]-alanine and [3H]-choline into SMMV was measured in 
quadruplicate at room temperature using a rapid filtration technique (Rüssel et al., 
1988) by the addition of 10 or 5 μΐ (approximately 8-4 μg protein) vesicles to 40 or 
195 ul extravesicular medium containing a tracer amount of radiolabeled solute, 
respectively. Uptake of 45CaCl2 into SMMV was determined according to van 
Heeswijk et al. (1984). Uptake was started by the addition of 10 ul vesicles (7-10 
μg) to 90 μΐ extravesicular medium, containing 0.5 mM CaCl2, EGTA, NTA and 
HEDTA with 5.13 mM MgCl2 and 3 mM ATP to obtain 1 μΜ free Ca
2+
 and 1.5 
mM Mg2+ in the presence of ATP and 2.3 mM MgCl2 to obtain 1 μΜ free Ca
2+
 and 
1.5 mM Mg2+ in the absence of ATP, all containing a tracer amount of 45Ca2+ and 
adjusted to 310 mosmol with 100 mM KCl and mannitol. For the calculations the 
dissociation constants between EGTA, NTA, HEDTA, Ca2+ and Mg2+ were used 
according to Ghijsen et al. (1982) with the computer program proposed by van 
Heeswijk et al. (1984). At appropriate time intervals the reaction was stopped by 
adding 2 ml ice cold intravesicular buffer or in case of Ca2+ uptake studies, 1 ml ice 
cold intravesicular buffer to which 0.1 mM LaCl3 was added to remove 
extravesicular bound Ca2+. The diluted samples of the alanine and choline uptake 
studies were filtered under vacuum through a glass fibre filter (Whatman GF/F) and 
in case of the Ca2+ uptake studies 900 μΐ of the diluted samples through a presoaked 
acetate/nitrate filter (Schleicher & Schuil ME25). The filters were washed twice and 
the radioactivity remaining on the filters was counted in a Beekman LS 6000 LL 
liquid scintillation counter. Corrections were made for aspecific filter binding. 
Uptakes are expressed as nmol or pmol/mg protein or as percentage of control 
uptake (mean ± SD or SE with N representing amount of experiments with different 
vesicle preparations). Transport conditions and control uptake in pmol/mg protein 
are given in the legends. 
For electron microscopy, the membrane suspension was centrifuged at 
1500*G for 10 min. Pellets were fixed in 2% glutardialdehyde in 0.1 M phosphate 
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buffer, pH=7.4 for 5 hours, washed and suspended in 2% agar (60 °C). The cured 
(at 4 °C for 30 min) agar was cut into small pieces, fixed in 2% glutardialdehyde, 
washed and post-fixed in 1.5% osmiumtetroxide in 0.1 M phosphate buffer. The 
blocks were washed and dehydrated in a series of graded alcohols. The dehydrated 
blocks were embedded in epon. Ultrathin sections were cut on a Reichert microtome 
(Vienna, Austria) and mounted on a 150 mesh uncoated copper grid. The sections 
were contrasted with 3.36% uranylacetate with lead citrate and examined in a 
Philips 300 transmission electron microscope (Eindhoven, the Netherlands) at 
60KV. 
Chemicals and materials 
[3H]-L-alanine (77 Ci/mmol) was obtained from New England Nuclear 
(Dreieich, Germany). 45CaCl2 (17 mCi/mg) and [3H]-choline (83 Ci/mmol) were 
obtained from Amersham (Buckinghamshire, UK). S(+)- and S(-)adrenaline were 
purchased from Sterling-Winthrop Research Institute (New York, NY), S(+/-
)cocaine from Genfarma (Maarssen, the Netherlands), and S(-)nicotine from Janssen 
Chimica (Beerse, Belgium). All other chemicals were purchased from either Sigma 
(St. Louis, MO), Merck (Darmstadt, Germany) or Boehringer Mannheim 
(Mannheim, Germany) and were of analytical grade. GF/F filters were obtained 
from Whatman Int. Ltd. (Maidstone, UK) and ME25 filters from Schleicher & 
Schüll (Dassel, Germany). 
Data analysis 
Paired Student's f-test was used to determine statistical significance (P<0.05). 
Curve fitting was done by least squares nonlinear regression analysis using the 
computer program PCNONLIN (Metzler and Weiner, 1989). 
Results 
Isolation characteristics 
Marker enzyme analysis revealed a 21-fold enrichment in alkaline 
phosphatase for SMMV. Addition of 0.1% saponin, triton X-100 or sodium-
deoxycholate to SMMV prior to incubation increased alkaline phosphatase slightly, 
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showing that approximately 90% of the vesicles were orientated right-side out, as is 
common for SMMV (Glazier et al., 1988). Na7K+ ATP-ase activity was nearly 5-
fold enriched. The SMMV preparation was not or to a very small extent enriched in 
succinate dehydrogenase and NADPH-cytochrome-C-reductase. Protein yield and 
specific activities and enrichment factors of the different marker enzymes are given 
in Table 1. Electron micrographs of the SMMV preparation are shown in Figure 1. 
Table 1. Protein recovery and specific activities of marker enzymes. 
Protein 
Alkaline phosphatase 
+saponin (0.1%) 
+tritonX-100 (0.1%) 
+deoxycholate (0.1 %) 
Na7K+ ATP-ase 
Succinate dehydrogenase 
Cytochrome-C-reductase 
Starting 
mince 
32 ± 8 
52 ± 16 
0.60 ± 0.02 
3.2 + 0.7 
4.6 + 1.2 
SMMV 
0.4 ± 0.1 
1080 + 390 
1210 ± 190 
1250 ± 380 
1210 ± 340 
3.0 ± 1.6 
2.9 ± 0.7 
6.6 ± 2.5 
Enrichment 
factor 
2 1 + 5 
4.9 + 4.3 
0.90 + 0.08 
1.4 + 0.8 
Yield 
(%) 
1.2 ±0.3 
N 
21 
21 
3 
3 
3 
5 
6 
6 
Data are presented as mg protein/g placenta wet weight for protein or pmol/h/mg protein for 
marker enzymes (means ± SD). 
•2*54. 
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Figure 1. Electron micrographs of SMMV. At low magnification (16000x, bar represents 1 pm) 
the membrane preparation appeared to be homogenous, vesicular and free of subcellular organelles 
(1). At high magnification (40000x, bar represents 200 nm) fragments of microvilli are visible and 
the microfilaments can be clearly distinguished (arrow) (2). 
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Ca2+ and alanine uptake 
45Ca2+ uptake into SMMV, as shown in Figure 2, was slightly stimulated by 
ATP and addition of A23187 did not result in Ca2+ release, indicating that Ca2+ was 
not accumulated into the vesicles. The inset curve shows ATP-dependent 
intravesicular accumulation of free Ca2+ into BMV, releasable with A23187. 
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Figure 2. Effect of ATP and A23187 on the uptake of 4SCa2+ into SMMV. Concentration of free 
Ca2+ was 1 μΜ, free Mg2* 1.5 шМ, ATP 3 шМ and A23187 10 μ$τη\. Vesicles were suspended in 
100 mM mannitol, 100 mM KCl and 10 mM Hepes-Tris, pH=7.4. Composition of the 
extravesicular media are described in Materials and Methods. Data are presented as nmol/mg 
protein (mean ± SE; N=3). Inset curve: Effect of ATP and A23187 on the uptake of 4SCa2+ into 
BMV. Conditions were the same as described for SMMV. 
Time-dependent uptake of 100 μΜ [3H]-alanine into SMMV is shown in 
Figure 3. An overshoot above equilibrium (peak vs. equilibrium at 30 sec=1.5) was 
seen in the presence of an inwardly directed Na+-gradient, providing evidence for 
sodium-dependent uptake against a concentration gradient. By permeabilizing 
SMMV in the presence of 0.1% saponin, uptake at 60 min (equilibrium) was 
reduced to approximately 20% of uptake without saponin, indicating intravesicular 
accumulation rather than non specific membrane binding. 
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Figure 3. Time-dependent uptake of 100 μΜ [3H]-alamne into SMMV in the presence and absence 
of an inwardly directed Na*-gradient. SMMV were suspended in 300 raM mannitol and 10 mM 
Hepes-Tns, pH=7 4 Extravesicular media consisted of 50 mM NaCl or 50 mM KCl, 200 mM 
mannitol and 10 mM Hepes-Tns, pH=7 4 Data are presented as pmol/mg protein (mean ± SD, 
N=10) 
The existence of mediated transport for alanine in SMMV was further 
evaluated by determining the concentration-dependent alanine uptake in the 
presence or absence of an inwardly directed Na+-gradient, which is shown in Figure 
4. The curve resulting from subtraction of the sodium-independent component (50 
mM K+-gradient) from the total uptake (50 mM Na+-gradient) shows saturability 
and could be described according to Michaelis-Menten kinetics. Nonlinear 
regression analysis revealed a K
m
 of 0.23 ± 0.07 mM and a V
m
„ of 359 ± 22 
pmol/mg/15 sec for sodium-dependent alanine uptake. 
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Figure 4. Concentration-dependent uptake of [3H]-alanine at 15 sec into SMMV. The curve 
represents the difference between uptake in the presence of an inwardly directed Na+- and K+-
gradient. Vesicles were suspended in 300 mM mannitol and 10 mM Hepes-Tris, pH=7.4. 
Extravesicular media consisted of 50 mM NaCl or 50 mM KCl and 10 mM Hepes-Tris, pH=7.4 
and 0.1-5 mM alanine adjusted to 310 mosmol with mannitol. Data are presented as pmol/mg 
protein (mean; N=2). 
Uptake at 15 sec of 100 μΜ alanine in the presence of an inwardly directed 
sodium gradient into SMMV was inhibited by 35 % in the presence of 5 mM 
glycine and by 52% in the presence of 5 mM phenylalanine as shown in Table 2. 
Uptakes at 1 min showed no overshoot and equilibrium uptake at 60 min in the 
presence of these amino acids was not affected. These results further confirmed the 
presence of mediated alanine transport and showed that interactions with active 
alanine transport can be demonstrated in our vesicles without an influence on 
vesicle volume. 
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Table 2. Effect of amino acids on alanine uptake into SMMV. 
Inhibitor 
control 
glycine 
phenylalanine 
mM 
5 
5 
15sec 
170 ± 6 0 
110 ± 4 0 * 
80 ± 30* 
60sec 
220 ± 70 
145 ± 16 
140 ± 50 
60min 
160 ± 4 0 
190 ± 30 
180 ± 30 
Uptake of 100 uM [3H]-alanine into SMMV in the presence of an inwardly directed 
sodium gradient. Vesicles were suspended in 300 mM mannitol and 10 mM Hepes-
Tris, pH=7.4. Extravesicular media consisted of 50 mM NaCl, 5 mM inhibitor, 10 
mM Hepes adjusted to pH=7.4 with Tris and to 310 mosmol with mannitol. Data are 
presented as pmol/mg protein or % of control uptake (mean ± SD, N=4). * P<0.05. 
Interaction with alanine and choline transport 
The effect of several drugs on alanine uptake is shown in Table 3. None of 
the drugs were able to inhibit alanine uptake significantly, except for indomethacin. 
Since uptake at 60 min (equilibrium) was also reduced to 60 % of control uptake it 
is difficult to ascribe this inhibition to a direct effect on the alanine transporter. In 
the presence of all other inhibitors peak uptake at 60 sec and equilibrium uptake at 
60 min was not altered (data not shown). 
Since cocaine competes with re-uptake of catecholamines in adrenergic 
neurons and a direct interaction of S(-)cocaine with the alanine transporter was 
suggested by Dicke et al. (1993), the potency of S(+)adrenaline, S(-)adrenaline and 
S(+/-)noradrenaline to interfere with alanine uptake into our SMMV was also 
evaluated. Uptake of alanine at 15 sec was not influenced by either of the 
compounds, viz. 99 ± 17, 97 ± 13 and 93 ± 4 % (mean ± SD, N=4) of 
representative control uptake, respectively. 
Initial uptake of 250 μΜ choline in the presence of an outwardly directed 
choline gradient (trans stimulation conditions) was significantly inhibited by several 
cationic drugs as is shown in Table 4. 
Table 3. Effect of several drugs on alanine uptake into SMMV. 
Inhibitor 
None 
Anionic drugs 
probenecid 
acetylsalicylic acid 
sodium salicylate 
indomethacin 
furosemide 
valproate 
Cationic drugs 
Cimetidine 
famotidine 
Drugs of abuse 
cocaine 
nicotine 
cotinine 
ethanol 
mM 
5 
5 
5 
5 
5 
5 
5 
5 
1 
1 
1 
87 (0.4%) 
% control 
uptake 
100 
102 ± 16 
102 ± 8 
104 ± 7 
60 ± 12* 
87 ± 13 
99 ± 15 
111 ± 11 
98 ± 14 
94 ± 5 
103 ± 11 
107 ± 4 
99 ± 10 
N 
4 
4 
4 
4 
4 
4 
4 
4 
3 
3 
3 
3 
Uptake of 100 μΜ [3H]-alanme at 15 sec into SMMV in the presence of an inwardly 
directed sodium gradient Vesicles were suspended in 300 mM mannitol and 10 mM 
Hepes-Tns, pH=7.4 Extravesicular media consisted of 50 mM NaCl, inhibitor at the 
specified concentration, 10 mM Hepes adjusted to pH=7 4 with Tris and to 310 mosmol 
with mannitol. Data are presented as % of representative control uptake (mean ± SD) 
Mean control uptake was 208 ± 71 pmol/mg protein (mean ± SD, N=9) * P<0 05 
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5 
5 
5 
5 
5 
5 
100 
15 ± 5 * 
22 ± 8 * 
46 ± 4 * 
48 ± 7 * 
66 ± 14* 
72 ± 9 * 
Table 4. Effect of cationic drugs on choline uptake into SMMV. 
Inhibitor mM % control uptake 
None 
Hemicholinium-3 
Atropine 
Cimetidine 
Ranitidine 
Propranolol 
Procainamide 
Uptake of 250 uM-[3H]-choline at 10 sec into SMMV in the presence of an outwardly 
directed choline gradient. Vesicles, suspended in 100 mM mannitol, 100 mM KCl and 
10 mM Hepes-Tris, pH=7.4, were pre-equilibrated with 5 mM unlabeled choline and 
20 uM valinomycin at 37 °C. Extravesicular media consisted of 100 mM mannitol, 100 
mM KCl, 20 μΜ valinomycin, 10 mM Hepes-Tris, pH=7.4, 5 mM inhibitor and 
unlabeled choline to achieve an extravesicular concentration of 250 μΜ. Data are 
presented as % of representative control uptake (mean ± SD, n=3 or 4). Mean control 
uptake was 5003 ± 498 pmol/mg protein (mean ± SD, N=4). * P<0.05 
Discussion 
In this report we describe the marker enzyme and transport characteristics of 
SMMV from human term placenta isolated according to an established, but slightly 
modified method. The SMMV were used to investigate drug-nutrient interactions of 
several commonly used drugs with the alanine and choline transporter. 
SMMV were isolated according to a procedure originally described for the 
isolation of rabbit renal brush-border membrane vesicles (Booth et al., 1974), but 
proven to be useful also for the isolation of human placental SMMV (Glazier et al., 
1988). However, to improve the isolation results we decided to replace the 
homogenization step of placental tissue by mincing the tissue in a Waring blender 
to pieces of approximately 5 mm3. Then the mince was stirred for 30 min to loosen 
the microvilli and filtered through gauze to remove large tissue parts, after which 
the procedure according to Glazier et al. (1988) was continued. These modifications 
doubled the protein recovery (0.6% to 1.2%) and increased alkaline phosphatase 
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enrichment slightly (18-fold to 22-fold). Apparent contamination of basal 
membranes in our SMMV was in the same range (5-fold enrichment in Na7K+ 
ATP-ase in our vesicles as compared to 6-fold enrichment in ouabaine binding in 
theirs). Although it is questioned in literature whether ATP-ases actually are located 
at the basal side of the human placenta exclusively (Eaton and Oakey, 1994), our 
modifications did not result in a higher contamination of ATP-ase containing 
structures. Contamination of subcellular organelles possibly interfering in transport 
studies, as mitochondria and endoplasmatic reticulum, was very small. Functional 
contamination of basal membranes is assumed to be negligible since no significant 
intravesicular accumulation of free Ca2+ in the presence of ATP could be 
determined. This effect was shown in BMV (Fisher et al., 1987 and Lafond et al., 
1991) and not in SMMV (Brunette et al., 1991 and Page et al., 1993), providing 
evidence for the location of an ATP-dependent Ca2+-transporter at the basal side in 
human placenta. However, Treinen and Kulkarni (1987) found ATP-stimulated 
uptake into SMMV. They concluded that this uptake might be into inside-out 
vesicles. Lafond et al. (1991) proposed that this effect might be a result of Ca2+-
stimulated alkaline phosphatase activity in SMMV. These factors might also be of 
influence in the small ATP-stimulated intravesicular Ca2+ uptake observed in our 
SMMV. We conclude that our SMMV are suitable for drug-nutrient interaction 
studies since alanine uptake was comparable to literature: sodium-coupled, 
inhibitable by structural analogues and saturable with kinetic parameters comparable 
to those reported by Johnson and Smith (1988) and Asai et al. (1982), Km = 0.39 
and 0.38 mM, respectively. The degree of inhibition of alanine uptake in the 
presence of a sodium gradient was the same as observed by Johnson and Smith 
(1988) and Enders et al. (1976). Obviously, the contribution of system L exceeded 
the contribution of system A in total alanine transport. As was proposed by Asai et 
al. (1982), alanine transfer is mediated by system A (inhibitable with glycine) with 
high affinity and by system L (inhibitable with phenylalanine) with low affinity. 
System ASC, another alanine transporting system, is assumed to be located in cell 
membranes other than SMM, e.g. BM (Johnson and Smith, 1988). 
Three groups of commonly used drugs during pregnancy were investigated 
for their potency to interact with alanine transport. Organic anions, as analgesics 
and the diuretic furosemide, did not inhibit alanine uptake, whereas they did inhibit 
p-aminohippurate uptake in SMMV (van der Aa et al., 1994a). It seems that the 
amino acid transport systems A and L are insensitive to anionic drugs. The cationic 
H2-receptor antagonists had no influence on alanine transfer either. However 
various cationic drugs were able to inhibit active uptake of the essential cationic 
Isolated membrane vesicles and drug-nutrient interaction studies 51 
nutrient choline. Inhibitor concentrations used were very high, consequently no 
conclusions can be drawn yet on the possible clinical implications of the observed 
inhibition of choline transfer. The drugs of abuse ethanol and nicotine, did not 
impair АШ transport in human placental perfused cotyledon and microvillous 
vesicles (Schenker et al., 1989a, 1989ь). No inhibition of alanine transport was 
observed in our vesicles in the presence of high concentrations of nicotine, its 
metabolite cotinine, and ethanol. Thus, also in our study no evidence was found that 
fetal growth retardation after extensive ethanol consumption or nicotine exposition 
is related to a direct effect on amino acid membrane transport. Uptake of several 
amino acids, however, was decreased in human placental villi in the presence of 
high concentrations of morphine, nicotine and cocaine, but it was not clear whether 
the interaction was due to competition for the amino acid carriers (Barnwell and 
Rama Sastry, 1983). A more complex relationship was assumed between these 
drugs, Ca2+-fluxes, cholinergic system and amino acid transport (Sastry et al., 1977, 
1983). In this respect the report by Dicke et al. (1993), who observed 
stereoselective inhibition of sodium-dependent alanine uptake into human placental 
SMMV in the presence of low doses S(-)cocaine, is of special interest. Their results 
suggest a direct interaction of S(-)cocaine with the alanine transporter and are in 
contrast with our observations, where no inhibition was found in the presence of 
cocaine, S(+)- and S(-)adrenaline and S(+/-)noradrenaline. However, the inhibition 
they observed was low and it is questionable whether uptake at 1 min in their 
experiments can be considered as a true measure of initial transport rate, since 
uptake at 30 sec or later clearly deviated from linearity in our experiments (Figure 
3). Another difference is that our control uptake at 15 sec was about 3000 times 
higher than their uptake at 1 min. Probably the sensitivity of the alanine transporter 
to exogenous compounds is higher at low alanine concentrations. Because maternal 
plasma contains a relatively high concentration of alanine (0.25 umol/ml; Philipps et 
al., 1978), low alanine concentrations are not likely to occur in vivo. Even when a 
cocaine-addicted mother is underfed, fetal growth retardation would be merely a 
result of malnutrition itself than an interaction of cocaine with amino acid transport. 
In conclusion, our SMMV showed marker enzyme, microscopic and 
functional characteristics in accordance with literature. Uptake of alanine, the most 
abundant amino acid in maternal plasma, was sodium-dependent, saturable and 
inhibitable by structural analogues. Commonly used drugs, like analgesics, H2-
receptor antagonists and drugs of abuse did not interact with alanine transport, 
whereas several cationic drugs inhibited choline uptake. The membrane vesicles 
isolated and used in this study provide a suitable tool for screening the inhibitory 
52 
potency of drags on nutrient transporters. 
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Summary 
The mechanism of uptake of p-aminohippurate (PAH) by syncytial 
microvillous membrane vesicles of human term placenta was investigated. Initial 
PAH uptake and efflux were increased in the presence of a pH-gradient and а СГ-
gradient, respectively. Forced negative and positive membrane potentials did not 
influence the uptake, which indicated that the transport is not electrogenic. The pH-
dependent increase is probably the result of a higher rate of diffusion due to a lower 
degree of dissociation of PAH. Because several organic anions failed to trans 
stimulate PAH uptake and FCCP did not decrease the uptake in the presence of an 
inwardly directed H+-gradient, ruling out an РАН/ОН' antiport, an anion exchange 
system does not appear to be present in these membranes. Since electrogenicity and 
anion exchange seem not to be involved in the СГ-dependent increase, an allosteric 
effect of CI" on the transporter might be possible. 
Various organic anions were able to inhibit pH-stimulated PAH uptake 
significantly. Kinetic analysis of the probenecid sensitive part of uptake provided 
further evidence for mediated transport of PAH (!£„= 7.4 ± 2.6 mM and Vm„= 2.0 
± 0.4 nmol/mg/15sec). Non-inhibitable diffusion accounted for the main part of total 
transport. Concentration dependent inhibition of PAH transport by probenecid 
showed a K, of 2.5 ± 0.9 mM. 
It is concluded that human placental syncytial microvillous membrane 
vesicles possess a low affinity transport mechanism for PAH with low specificity. 
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The importance of this system, for placental excretion of anionic drugs, will depend 
on the intrasyncytial concentration of these drugs, caused by the transport across the 
basal membrane. 
Introduction 
The human placenta, a polarised epithelium, like intestine, kidney and blood-
brain barrier, is the crucial organ for absorption of nutrients and excretion of waste 
products necessary for fetal growth and development. Transport systems of the 
syncytiotrophoblast mediating absorption and excretion will be present in the 
syncytial microvillous membrane (SMM) and the basal membrane (BM) (Whitsett, 
1980). 
The majority of drugs are sufficiently lipophilic to cross the placenta by 
passive diffusion and to reach the fetal circulation (Chamberlain, 1986). Very little 
is known on the role of the placenta in eliminating drugs. Ganapathy et al. 
postulated that the human placental organic cation-proton antiporter may participate 
in eliminating cationic drugs from the fetal circulation (Ganapathy et al., 1988). In 
only one study, on the transfer of the anionic drug p-aminohippurate (PAH), in 
sheep placenta in vivo, no evidence was found for active transport (Mc Nay et al., 
1969). Because of the fact that analgesics are the second most widely taken group 
of drugs during pregnancy (Bonati et al., 1990) it is relevant to get more 
information on the transport of anionic drugs across the human placenta. Membrane 
vesicles isolated from human term placenta have proven their usefulness in studying 
transport characteristics of compounds across separate membranes of the 
syncytiotrophoblast, without the limitations of species differences. 
The present study was designed to investigate the characteristics of the 
transport of PAH, a model substrate for anionic drugs in kidney studies, in isolated 
syncytial microvillous membrane vesicles (SMMV) of human term placenta. 
Materials and methods 
Vesicle preparation 
Human placental SMMV were prepared according to previously described 
procedures (Glazier et al., 1988; Glazier et al., 1990), which are essentially based 
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on a method for the isolation of brush-border membranes from rabbit kidney (Booth 
and Kenny, 1974). Placentas were obtained within 15 min after vaginal delivery. 
Fetal membranes and decidua were removed and the villous tissue was dissected 
and homogenized in a Warring Blender and Potter Elvjehem. At this point a 
modification was introduced: the homogenate was stirred for 30 min to loosen the 
microvilli. After MgCl2 aggregation of contaminating membranes and differential 
centrifugation, both steps repeated once, the SMMV were obtained and suspended 
in an appropriate buffer to reach a final protein concentration of 10-15 mg/ml. The 
vesicles were frozen in N2(l) and stored at - 80°C until use. All subsequent steps 
were performed at 4°C. 
Enzyme analysis 
Purification was determined by assaying the specific activity in SMMV 
relative to the specific activity in the homogenate of the following marker enzymes 
according to previously described methods: alkaline phosphatase for SMM 
(Mircheff and Wright, 1976), Na7K+ ATP-ase for BM (Schoot et al., 1977), 
succinate dehydrogenase for mitochondria (Pennington, 1961), NADPH-dependent 
cytochrome-C-reductase for smooth endoplasmatic reticulum (Omura and Takesue, 
1970) and cathepsin-D for lysosomes (Anson, 1938). The orientation of the vesicles 
was determined by assaying the alkaline phosphatase activity with and without 
previous treatment with 0.1 % saponin. Protein was assayed with a coomassie blue 
kit (Biorad, München, Germany) with bovine serum albumin as standard. 
Transport studies 
The uptake of [3H]-L-alanine and [3H]-PAH into SMMV was measured in 
quadruplicate at 20°C and 37°C, respectively, using a rapid filtration technique 
(Schwab et al., 1984). Generally uptake was started by the addition of 10 ul (10-15 
μg protein) membrane suspension to 40 ul extravesicular medium. In case of efflux 
studies 90 μΐ and in case of trans stimulation studies 190 ul extravesicular medium 
was used. In general the extravesicular media consisted of 10 mM Hepes-Tris, 
pH=7.4 or 10 mM Mes-Tris, pH=6.0 with the appropriate gradients adjusted to 310 
mosmol with mannitol to which radiolabeled substrates were added. In case of trans 
stimulation studies, vesicles, suspended in 300 mM mannitol and 10 mM Hepes-
Tris, pH=7.4, were preequilibrated with 500 μΜ unlabelled PAH, 1 mM 
furosemide, 1 mM probenecid or 1 mM urate for 60 min at 37°C. Efflux studies 
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were carried out with SMMV preequilibrated with 100 μΜ [3H]-PAH for 60 min at 
37°C. Exact composition of the transport conditions are given in the legends. 
At appropriate time intervals the reaction was stopped by adding 2 ml of ice-
cold stop buffer with the same composition as the intravesicular medium, except in 
case of membrane binding studies in which the stop buffers were equal to the 
extravesicular medium. The sample was filtered under vacuum through a Whatman 
GF/F-filter and washed twice. The radioactivity remaining on the filter was counted 
in a Beekman LS 6000 LL liquid scintillation counter. Corrections were made for 
aspecific filter binding. Uptake is expressed as pmol or nmol/mg protein and efflux 
as % of equilibrium uptake (mean ± SD). All transport experiments were conducted 
at least 3 times with 2 placentas. 
Paired Student's t-test was used to determine statistical significance (P<0.05). 
Curve fitting was done by least-squares nonlinear regression analysis using the 
computer programme PCNONLIN (Metzler and Weiner, 1989) for the 
determination of K,,, and V
mM and the computer programme GraphPad INPLOT 
(4.0) (GraphPad Software, 1992) for the determination of K,. 
Chemicals and materials 
[3H]-L-alanine was obtained from New England Nuclear (Dreieich, Germany) 
and [3H]-p-aminohippurate from Amersham (Buckinghamshire, U.K.). All other 
chemicals were purchased from either Sigma (St. Louis, U.S.A.), Merck (Darmstadt, 
Germany) or Boehringer (Mannheim, Germany) and were of analytical grade. GF/F-
filters were obtained from Whatman Int. Ltd. (Maidstone, U.K.) 
Results 
Vesicle preparation 
Enzyme analysis revealed a 14-fold enrichment of alkaline phosphatase for 
SMMV over homogenate. Specific activities: 550 ± 220 and 40 ± 13 μιηοΐ/hr/mg 
protein (N=11), respectively. This result is in accordance with previous reports 
(Glazier et al., 1988). The SMMV preparation was not enriched in mitochondria, 
smooth endoplasmatic reticulum or lysosomes (enrichment factors: 0.7, 1.3 and 0.1, 
respectively). The vesicle preparation showed a 5-fold enrichment in Na7K+ ATP­
ase over homogenate. Specific activities: 16 ± 7 and 3 ± 2 umol/hr/mg protein 
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(N=11), respectively. The specific activity of Na+/K+ ATP-ase in human placenta is 
very low and therefore difficult to detect in the starting homogenate. A small 
contamination would result in an apparently high enrichment (Brunette and Allard, 
1985; Karl et al., 1989). 
Adding 0.1% saponin previous to enzyme analysis slightly increased the 
specific activity of alkaline phosphatase in SMMV (285 + 80 versus 315 ± 115 
umol/hr/mg protein, N=3), which indicated that the vast majority of the vesicles 
were orientated right-side-out (>90%). 
The procedure yielded approximately 50 mg protein/150 g placenta tissue. 
Functional validation 
The isolated membrane vesicles were validated functionally by measuring the 
Na+-gradient dependent L-alanine uptake, which is present in SMM (Johnson and 
Smith, 1988). Figure 1 shows the time course of 100 uM L-alanine uptake into 
SMMV in the presence of an inwardly directed 50 mM Na+- or 50 mM K+-gradient. 
In the presence of a Na+-gradient an overshoot above equilibrium value (peak vs. 
equilibrium^.5) of the uptake of L-alanine was observed. Uptake at 2 min in the 
presence of a Na+-gradient was 2.3-fold enhanced over that observed in the presence 
of a K+-gradient. Freezing N2(l) and storage (-80°C) for 1 month did not influence 
the alanine transport (data not shown). 
PAH transport 
1. Effect of different transport conditions 
Uptake of 100 μΜ PAH at 15 sec into SMMV, as shown in Table 1, was 
increased significantly in the presence of an inwardly directed 100 mM Na+- and 
100 mM K+-gradient (pH=pH0=7.4) and an inwardly directed H+-gradient 
(pH,=7.4/pH
o
=6.0) compared to pH=pH0=7.4, (P<0.05). The pH-dependent PAH 
uptake was not influenced by the addition of 10 pg/mg protein of the proton 
ionophore FCCP. As shown in Table 2 a valinomycin induced inside negative or 
positive membrane potential did not influence PAH uptake at 15 sec compared to 
short-circuited and control membrane vesicles. Uptakes in the presence of equal 
intra- and extravesicular concentrations of Na+ or K+ were in the same range as 
uptakes in the presence of inwardly directed gradients of Na+ or K+ (Table 1 and 2). 
Loading the vesicles with 500 μΜ unlabelled PAH, 1 mM furosemide, 1 mM 
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probenecid or 1 mM urate did not trans stimulate the PAH uptake (32 ± 6, 37 ± 13, 
34 ± 11 and 31 ± 7 (pmol/mg protein), respectively). In the presence of a H+-
gradient uptake of 100 uM PAH could be inhibited significantly by the addition of 
5 mM probenecid, (P<0.05). 
300 г 
50 mM Na* 
50 mM K* 
Ï 
1 
60 
Figure 1. Time dependent uptake of 100 uM [3H]-L-alanine into SMMV in the presence of an 
inwardly directed 50 mM Na*- or 50 mM K+-gradient. The vesicles were suspended in 300 mM 
mannitol and 10 mM Hepes-Tris, pH=7.4. The extravesicular medium consisted of 200 mM 
mannitol, 50 mM NaCl or 50 mM KCl and 10 mM Hepes-Tris, pH=7.4. Values are expressed as 
pmol/mg protein (mean ± SD). 
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Table 1. Effect of different transport conditions 
Extravesicular medium 
pH=7.4 
pH=6.0 
100 mM Na+ 
lOOmMK* 
pH=6.0 + 5 mM probenecid 
pH=6.0 -FCCP 
pH=6.0 + FCCP 
Uptake 
30 ± 8 
65 ± 18 
51 ± 7 
53 ± 9 
41 ± 10 
52 ± 15 
50 ± 12 
Uptake of 100 μΜ [3H]-PAH at 15 sec in different 
extravesicular media in a 10 mM Hepes-Tris, pH=7.4 or 
10 mM Mes-Tris, pH=6.0 buffer with the specified 
gradient adjusted to 310 mosmol with mannitol. 
Vesicles were suspended in 300 mM mannitol and 10 
mM Hepes-Tris, pH=7.4. In case of FCCP studies 
vesicles were preequilibrated with FCCP, dissolved in 
ethanol, for 60 min at 37°C. The same amount of 
ethanol was added to the controls. Values are expressed 
as pmol/mg protein (mean ± SD). 
Table 2. Effect of membrane potential 
Transport condition Uptake 
K+,=K+
o
=0 mM/Na+,=Na+
o
=100 mM 56 ± 8 
K+,=K>100 mM/Na+,=Na+
o
=0 mM 52 ± 6 
K>100 mM,K>0 mM/Na+,=0mM, Na>100 mM 53 ± 7 
K+,=0 mM,K+
o
=100 mM/Na>100 mM,Na+
o
=0 mM 58 ± 2 
Uptake of 100 μΜ [3H]-PAU at 15 sec in different intra- and extravesicular 
media in the presence of 10 μ§/ιτ^ protein valinomycin. Vesicles were 
suspended in 100 mM mannitol, 100 mM K-gluconate or 100 mM Na-gluconate 
and 10 mM Hepes-Tris, pH=7.4. Extravesicular media consisted of 100 mM 
mannitol, 100 mM K-gluconate or 100 mM Na-gluconate and 10 mM Hepes-
Tris, pH=7.4. Vesicles were preequilibrated at 37°C for 60 min with 10 μ^ιτ^ 
protein valinomycin in ethanol, which was evaporated under N2. Values are 
expressed as pmol/mg protein (mean ± SD). 
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Figure 2 shows the time course of the uptake of 100 μΜ PAH into SMMV in the 
presence of an inwardly directed H+-gradient with and without 5 mM probenecid. 
PAH was rapidly taken up during the first 60 sec and reached equilibrium after 60 
min. Equilibrium uptake was not affected by probenecid (data not shown). As 
shown in Figure 3, efflux of 100 μΜ PAH out of SMMV was significantly 
enhanced in the presence of an inwardly directed CI -gradient, whereas S04
2
" did not 
significantly enhance the efflux. 
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Figure 2. Time dependent uptake of 100 μΜ [3H]-PAH into SMMV in the presence of an inwardly 
directed H+-gradient with or without 5 mM probenecid. Vesicles were suspended in 300 mM 
mannitol and 10 mM Hepes-Ths, pH=7.4 Extravesicular medium consisted of 300 mM mannitol 
and 10 mM Mes-Tns, pH=6 0. Values are expressed as pmol/mg protein (mean ± SD). Inset: Time 
dependent PAH uptake until equilibrium with the same transport conditions. 
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Figure 3. Efflux of 100 uM [3H]-PAH at 15 sec out of SMMV in the presence or absence of an 
inwardly directed 50 mM СГ- or S04
2
'-gradient. Vesicles were suspended in 200 mM mannitol, 50 
mM K-gluconate, 10 mM Hepes-Tris, pH=7.4 in case of СГ- and 100 mM mannitol, 100 mM K-
gluconate, 10 mM Hepes-Tris, pH=7.4 in case of S04
2
"-efflux studies. Extravesicular medium 
consisted of 200 mM mannitol, 50 mM KCl, 10 mM Hepes-Tris, pH=7.4 in case of СГ- and 150 
mM mannitol, 50 mM K2S04, 10 mM Hepes-Tris, pH=7.4 in case of S04
2
"-efflux studies. Values 
are expressed as % of equilibrium uptake (mean ± SD). Equilibrium uptake after 60 min was 370 
± 35 pmol/mg protein for СГ- and 277 ± 33 pmol/mg protein for S04
2
"-efflux studies (mean ± SD). 
* P<0.05. _ 
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Figure 4. Effect of extravesicular pH on the 30 sec uptake of 100 μΜ [3H]-PAH into SMMV. 
Vesicles were suspended in 300 mM mannitol and 10 mM Hepes-Tris, pH=7.4. Extravesicular 
medium consisted of 300 mM mannitol of which the pH was varied by changing the 
concentrations of Hepes, Mes and Tris, but total amount of Hepes or Mes + Tris was maintained at 
10 mM. Data are expressed as pmol/mg protein (mean ± SD). 
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2. Effect of extravesicular pH 
Since PAH is an organic anion with a pK
a
 of 3.8 it exists predominantly in 
the dissociated form at physiologic pH. We determined the effect of extravesicular 
pH on the uptake of 100 μΜ PAH. As shown in Figure 4 decreasing the 
extravesicular pH increased the PAH uptake. 
3. Determination of membrane binding 
To discriminate between uptake into SMMV and membrane binding we 
determined the dependence of PAH uptake on medium osmolality. Figure 5 shows 
an inverse relation between the uptake of 100 uM PAH and osmotic pressure 
measured after 90 min (Y=71.15*X+11.81, R2=0.9998). Extrapolation to infinite 
osmolality indicated a small degree of membrane binding (±5%) 
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Figure 5. Effect of increasing osmotic pressure on equilibrium uptake (90 min) of 100 μΜ [3H]-
PAH into SMMV Vesicles were suspended in 300 mM mannitol and 10 mM Hepes-Tns, pH=7 4. 
Extravesicular media consisted of 10 mM Mes-Tns, pH=6 0 and increasing concentrations of 
mannitol. Stop buffers had the same composition as the extravesicular media Values are expressed 
as pmol/mg protein against reciprocal osmolality (mean ± SD). 
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4. Effect of organic anions 
As was shown in Figure 2 and Table 1 probenecid was able to inhibit PAH 
uptake. This is indicative of the existence of mediated transport for PAH in SMMV. 
To examine the specificity of the carrier we determined the effect of various 
organic anions on uptake of 100 uM PAH in the presence of an inwardly directed 
H+-gradient. Table 3 shows that anionic drugs, except salicylate, inhibited PAH 
uptake, whereas urate did not inhibit uptake. 
Table 3. Effect of organic anions on PAH uptake 
Organic ion 
control 
probenecid 
DIDS 
furosemide 
indomethacin 
salicylate 
urate 
mM 
5 
1 
5 
2.5 
5 
1 
% Uptake 
100 
62 ± 1 7 * 
65 ± 1 5 * 
56 ± 8 * 
62 ± 5 * 
96 ± 23 
90 ± 27 
Effect of various organic anions on the 15 sec uptake of 
100 uM [3H]-PAH in the presence of an inwardly 
directed H*-gradient. Experimental conditions were 
similar to those given in the legend of Figure 2. Results 
are expressed relative to representive control uptakes 
(mean ± SD). * P<0.05. 
5. Determination of kinetic parameters 
Further evidence for mediated transport was obtained from experiments in 
which the uptake of increasing concentrations of PAH was determined in the 
presence of an inwardly directed H+-gradient with and without 5 mM probenecid 
(Figure 6). Subtracting simple diffusion (that part of total uptake that could not be 
inhibited with probenecid) from the total uptake, resulted in a curve which could be 
described according to Michaelis-Menten kinetics. Least-squares nonlinear 
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regression analysis revealed a K^ , of 7.4 ± 2.6 mM and a V
mm
 of 2.0 ± 0.4 nmol/mg 
protein/15 sec. The inset curve shows the concentration dependent inhibition of the 
uptake of 100 uM PAH by probenecid in the presence of an inwardly directed H+-
gradient. Nonlinear regression analysis showed a K, of 2.5 + 0.9 mM. 
PAH (mM) 
Figure 6. Concentration dependent uptake of [3H]-PAH into SMMV in the presence of an inwardly 
directed H+-gradient with or without 5 mM probenecid. Experimental conditions were the same as 
described in the legend of Figure 2. Uptakes were measured at 15 sec in the presence of increasing 
concentrations PAH (0-10 mM). Values are expressed as nmol/mg protein (mean + SD). Inset: 
Effect of probenecid on the uptake of 100 μΜ [3H]-PAH in the presence of an inwardly directed 
H+-gradient. Experimental conditions were the same as described in the legend of Figure 2. 
Uptakes were measured at 15 sec in the presence of increasing concentrations probenecid (ΙΟ^-δ 
mM). Values are expressed as % uptake of control (without probenecid). Control uptake was 88 ± 
1 pmol/mg protein. 
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Discussion 
Our SMMV were enriched 14-fold in alkaline phosphatase, which was in 
accordance with the results reported by Glazier et al. (Glazier, Jones and Sibley, 
1988). They found a 6-fold enrichment in ouabain binding, which was in the same 
range as our 5-fold enrichment in Na+/K+ ATP-ase as marker for the contamination 
by basal membrane. Because Na+/K+ ATP-ase may also be found on plasma 
membranes of other placenta cells, the actual contamination of basal membrane will 
be lower (Illsley et al., 1990). 
To be sure that our preparation exhibited transport characteristic of SMM, we 
validated our vesicles functionally. Alanine uptake into SMMV showed an 
overshoot within 2 min in the presence of an inwardly directed Na+-gradient, which 
indicated a Na+-dependent uphill transport system for alanine in our membrane 
vesicles. This transport system has been described in SMMV (Johnson and Smith, 
1988) and not in BMV (Hoeltzli and Smith, 1989). 
Initial uptakes were increased in the presence of a pH-gradient, a Na+- and 
K+-gradient and equal intra- and extravesicular concentrations of Na+ or K+ as 
compared to uptake in a buffer with only mannitol. Under the experimental 
conditions an overshoot was not observed, but this does not exclude secondary 
active transport. The enhanced initial efflux in the presence of a СГ-gradient, as 
compared to a S04
2
"-gradient, could be the result of an exchange mechanism as has 
been described in brush-border membranes of dog kidney (Steffens, Holohan and 
Ross, 1989). However, since PAH, furosemide, probenecid and urate failed to trans 
stimulate PAH uptake an exchange mechanism in SMMV seems unlikely. Also the 
proton ionophore FCCP did not decrease the PAH uptake in the presence of an H+-
gradient, which means that proton transport is not directly involved in PAH uptake 
and a PAH/OH" exchange mechanism can be excluded. Forced inside positive and 
negative membrane potentials did not influence PAH uptake. The small increase in 
efflux in the presence of a СГ-gradient and in uptake in the presence of a Na+- and 
K+-gradient is therefore unlikely to be the result of an influence of the membrane 
potential on PAH transport. Since uptake in the presence of inwardly directed Na+-
and K+-gradients equals uptake in simply the presence of these ions, inreased uptake 
must be due to some influence of the ionic strength of the solutions rather than an 
effect of an altered membrane potential. Since electrogenicity and anion exchange 
seem not to be involved in the Cl"-dependent increase, an allosteric effect of СГ on 
the transporter, as was described by Inui et al. for rat renal basolateral membrane 
vesicles (Inui et al., 1986), might be possible. The increased initial uptake in the 
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presence of an H+-gradient is probably the result of a higher diffusion due to a 
lower degree of dissociation of PAH. It can be calculated that at pH=6.0, 0.6% and 
at pH=7.4, 0.03% of the total amount of PAH is in undissociated form. Membrane 
binding accounted for approximately 5% of the total uptake at pHo=6.0, and cannot 
be an explanation for the increased uptake compared to pH0=7.4. A pH-dependent 
increase in vesicle volume cannot be completely ruled out, but this should have 
minor influence on initial uptake values. The absence of an uphill co-transport 
system as a driving force for PAH transport, in our vesicles of human placenta, is 
in accordance with the lack of active transfer for PAH in sheep placenta (Mc Nay 
et al., 1969). 
Various organic anions were able to inhibit the initial pH-stimulated PAH 
uptake. These results suggest the presence of a mediated transport mechanism for 
PAH, with a relatively low specificity. The presence of a mediated process was 
confirmed by the observed saturability of PAH uptake. The kinetic parameters 
found provided evidence for a low affinity and high capacity transport system 
comparable with those demonstrated in brush-border membrane vesicles of dog 
kidney (Rüssel et al., 1988) and rat kidney (Bresler et al., 1989). Non-inhibital 
diffusion accounted for the main part of total transport. 
The in vivo role of this carrier remains to be elucidated. Fetal kidney starts 
to excrete waste products into the amniotic fluid approximately 5 months after 
conception (Smith, 1951). An excretory function of the placenta for organic anions, 
especially during the first 5 months, would therefore be meaningful. The carrier 
system may in vivo mediate the transport of anionic drugs across SMM into the 
maternal circulation by facilitated diffusion. Whether this system plays a role of 
importance in the elimination of anionic drugs from the fetal circulation in preterm 
placenta will strongly depend on the intrasyncytial concentration of these drugs, 
resulting from uptake at the basal membrane. 
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Summary 
Uptake of the H2-receptor antagonist, Cimetidine, into syncytial microvillous 
membrane vesicles of human term placenta was investigated to clarify whether an 
active transport mechanism can be responsible for the observed barrier of the 
human placenta for Cimetidine. Imposition of an outwardly directed H+-gradient 
stimulated Cimetidine uptake, resulting in a small transient overshoot. The H+-
gradient-dependent peak uptake was decreased under voltage clamped conditions by 
carbonyl cyanide p-trifluoromethoxy-phenylhydrazone (FCCP), suggesting the 
presence of an organic cation-proton exchange mechanism. Uptake was partially, 
but significantly, inhibited by organic cation transport inhibitors, H2-receptor 
antagonists and several other cationic drugs, providing further evidence for mediated 
uptake. H+-gradient-dependent Cimetidine uptake was saturable and characterized by 
a low affinity (K,J of 6.3 mM and
 гаал
 of 17.5 nmol/mg protein/10 sec. We 
conclude that the system cannot play an important role in the barrier function of the 
human placenta in the transport of Cimetidine. Rather than active transport, other 
factors, as for instance the degree of ionization of Cimetidine at physiological pH, 
seem to be a more likely explanation for the low clearance of Cimetidine across the 
human placenta. 
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Introduction 
H2-receptor antagonists, like Cimetidine and ranitidine, are frequently used 
therapeutic agents in the treatment of peptic ulcer in humans. Additionally, 
Cimetidine is sometimes used in the prevention of gastric acid aspiration for women 
at labour under general anaesthesia (McGowan, 1979). 
The guanidine-analogues ranitidine (Mihaly et al., 1982) and Cimetidine 
(Mihaly et al., 1983) cross the placenta in pregnant ewes at near term. Fetal plasma 
concentrations, however, were much lower than maternal plasma concentrations 
after maternal dosage. This trans placental gradient was reported to be due to the 
placenta itself (e.g. active transport from fetus to mother, irreversible placental 
metabolic elimination), since fetal renal elimination did not play an important role 
(Mihaly et al., 1983). In a follow-up study the trans placental gradient could not be 
explained by a low placental permeability or differential plasma protein binding of 
Cimetidine between mother and fetus (Ching et al., 1985). 
Cimetidine, administered to women at labour, showed a slow placental 
transfer finally achieving equal concentrations in maternal and fetal plasma. Protein 
binding or placental metabolism was a minor influence. Because the concentration 
of Cimetidine in the amniotic fluid was raised and there was a decreasing 
concentration in the cord blood, a role for fetal renal elimination seemed likely 
(Howe et al., 1981). However, since the fetal kidney begins to excrete waste 
products approximately five months after conception, the placenta could play a role 
in the elimination of cationic drugs before five months. 
In the perfused human placental cotyledon, the clearance of Cimetidine was 
low, providing evidence for a barrier function of the placenta in Cimetidine transfer 
(Ching et al., 1987). Since fetal and maternal plasma concentrations did equilibrate, 
active transport appeared to play an insignificant role in maintaining a barrier across 
the human placenta. The absence of mediated transport was confirmed by Schenker 
et al. (1987), using the same experimental technique. The maternal to fetal transfer 
of Cimetidine showed no signs of accumulation, saturability or susceptibility to 
inhibition by structural analogues. In this study, no evidence was found also for the 
saturation of Cimetidine uptake in microvillous membrane vesicles of human term 
placenta. However, concentrations of up to only 400 μΜ were used and no driving 
forces were applied. 
More precise information concerning the driving forces, specificity and 
saturability of transport could provide better insight into the underlying mechanism 
of the low clearance for Cimetidine across the human placenta. The present study 
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was designed to investigate in more detail the molecular mechanisms of Cimetidine 
transport across the human term placenta by using isolated syncytial microvillous 
membrane vesicles (SMMV). 
Materials and Methods 
Vesicle preparation 
Human placental SMMV were prepared according to a modification of the 
procedure described by Glazier et al. (1988) as method number three. Briefly, tissue 
obtained within 15 min after uncomplicated delivery was minced in a Warring 
blender and stirred for 30 min to loosen the microvilli. After MgCl2 aggregation and 
differential centrifugation, both steps repeated once, SMMV were harvested and 
suspended in an appropriate buffer. The protein concentration of SMMV used in 
this study was 10.4 ± 2.2 mg/ml (N=23). All subsequent steps were performed at 
4°C. Vesicles were frozen in N2(l) and stored at -80°C for 4 weeks at the 
maximum. Protein was assayed with a coomassie blue kit (Biorad, München, 
Germany). Alkaline phosphatase enrichment of SMMV, measured according to 
Mircheff and Wright (1976), was 22-fold as compared to starting mince (M0: 60 ± 
20, SMMV: 1350 ± 570 μιαοΙ/hJmg, N=14). 
Uptake studies 
Uptake of [3H]-cimetidine into SMMV was measured in quadruplicate at 
37°C, using a rapid filtration technique (Rüssel et al., 1988). Uptake was started by 
addition of 10 μΐ membrane suspension to 40 μΐ extravesicular medium containing 
radiolabeled compound. The transport conditions are given in the legends. At 
appropriate time intervals, the reaction was terminated by adding 2 ml of ice-cold 
stop solution with the same composition as the intravesicular medium, except for 
membrane binding studies in which the stop solutions were equal to the 
corresponding extravesicular media. The samples were filtered under vacuum 
through a Whatman GF/F glass fibre filter and washed threefold. Radioactivity 
remaining at the filter was counted in a Beekman LS 6000 LL liquid scintillation 
counter. Corrections were made for nonspecific filter binding. 
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Data analysis 
Data are presented as means ± SD, with N representing the number of 
experiments with different vesicle preparations. Statistical significance of differences 
in Cimetidine uptake was determined with the use of two-tailed, paired Student's t-
test (P<.05). Curve fitting was done by least squares nonlinear regression analysis, 
using the computer program PCNONLIN (Metzler and Weiner, 1989). 
Chemicals 
[3H]-Cimetidine (21 Ci/mmol) was obtained from Amersham (Aylesbury, 
U.K.). Cimetidine was generously donated by Smith, Kline & French Laboratories 
(Herts, U.K.), nizatidine by EU Lilly & Company (Indianapolis, IN) and 
trimethoprim by Bergel (the Netherlands). Mepiperphenidol and famotidine were 
generously donated by Merck, Sharpe & Dohme (Rahway, NY), n-
Methylnicotinamide (NMN) and tetraethyl-ammoniumbromide (TEA) were 
purchased from Janssen Chimica (Beerse, Belgium). All other chemicals were 
purchased from either Sigma (St Louis, MO), Merck (Darmstadt, Germany) or 
Boehringer (Mannheim, Germany). GF/F filters were obtained from Whatman Int. 
Ltd (Maidstone, U.K.). 
Results 
H*-gradient-dependent uptake of Cimetidine 
The outwardly directed proton gradient (pH=6.0/pH
o
=7.4) stimulated 
Cimetidine (20 μΜ) uptake into SMMV, resulting in a small, but significant, 
transient overshoot (peak vs. equilibrium=1.3) as compared to uptake in the absence 
of a H+-gradient (pH=pH0=7.4) (Figure 1). The difference in equilibrium uptake at 
60 min is probably due to a pH-dependent increase in vesicle volume, but this 
should have minor effects on initial uptake values. 
Effect of ionophores on H*-gradient uptake 
To determine whether the stimulated uptake of Cimetidine in the presence of 
a proton-gradient was due to the activity of an organic cation-proton antiport system 
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or a H+-diffusion potential the effect of the proton ionophore FCCP was evaluated. 
FCCP causes an enhanced H+-flux down its concentration gradient, which lowers 
the availability of H+ for a possible cation-proton exchanger and consequently 
decreases the uptake of the cation. The FCCP induced H+-flux also renders the 
inside of the vesicle more negative resulting in an increase of uptake of the cation if 
uptake is dependent on a H+-diffusion potential. As shown in Table 1, FCCP did 
not increase the H+-gradient-dependent initial and peak uptake rates. These results 
show that an inside negative H+-diffusion potential is unlikely to be a driving force 
for Cimetidine uptake. However, in voltage clamped vesicles (equal amounts of 
potassium at both sides of the membrane in presence of the KMonophore 
valinomycin), in which peak and equilibrium uptakes were not significantly altered, 
FCCP was able to decrease Cimetidine uptake, resulting in a diminished overshoot. 
The decreased uptake suggests an organic cation-proton exchanger responsible for 
the small transient overshoot. 
о 
IH ft 
00 
'о 
в 
ft 
о M 
л 
ft 
3 
υ 
ö 
В 
3υυ 
200 
100 
_о_ ρΗ,-ρΗ,,-
-+- р Н
Г
 6.0 
h-
in 
ι 
7.4 
/ pH„- 7.4 
1 
-г 
· 
χ 
о 
10 20 30 
Τ 
о 
1 
60 
time (min) 
Figure 1. Time-dependent uptake of 20 μΜ [3H]-cimetidine into SMMV in the presence or 
absence of an outwardly directed rT-gradient. Vesicles were suspended in 300 mM mannitol and 
10 mM Mes-Tris, pH=6.0 or 10 mM Hepes-Tris, pH=7.4. Extravesicular medium consisted of 300 
mM mannitol and 10 mM Hepes-Tris, pH=7.4. Values are expressed as pmol/mg protein (N=11). 
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Uptake 
10 sec 
47 ± 9 
87 ± 9 
84 ± 16 
60 sec 
67 ± 
176 ± 
172 ± 
23 
34 
36 
60 min 
78 ± 21 
148 ± 26 
154 ± 18 
Table 1. Effect of H*-gradients and ionophores on Cimetidine uptake 
Condition 
pH=7.4/pH0=7.4 
рН.^.О/рН^Д 
pHi=6.0/pHo=7.4+FCCP 
В pH,=6.0/pH„=7.4+val+FCCP 57 ± 12 108 ± 34 130 ± 35 
Uptake of 20 uM [3H]-cimetidine into vesicles suspended in 300 raM mannitol and 10 mM Hepes-
Tris, pH=7.4 or 10 mM Mes-Tris, pH=6.0 (A) or 100 mM mannitol, 100 mM KCl and 10 mM 
Mes-Tris, pH=6.0 (B). Extravesicular media consisted of 300 mM mannitol and 10 mM Hepes-
Tris, pH=7.4 (A) or 100 mM mannitol, 100 mM KCl and 10 mM Hepes-Tris, pH=7.4 (B). 
Vesicles were preequilibrated for 60 min at 37°C with 20 uM valinomycin (val) and/or 40 uM 
FCCP. FCCP (40 uM) was also added to the extravesicular medium. Data are presented as 
pmol/mg protein (N=3). 
Determination of membrane binding 
Figure 2 shows that the uptake of 20 uM Cimetidine was inversely related to 
medium osmolality (R2 > 0.81 of individual regression lines), indicating transport 
into an osmotically responsive intravesicular space. Because of the large variation in 
uptake data between different placentas, only a rough estimate could be made of the 
actual intravesicular uptake, which accounted for 77 ± 27 % of total uptake 
Effect of organic cations 
The inhibitory effect of various organic cations on Cimetidine uptake was 
investigated. Table 2 shows the initial H+-gradient-dependent uptake of 20 uM 
Cimetidine as percentage of representative control uptake in the presence of 1 or 5 
mM inhibitor. The prototypic organic cation transport inhibitors mepiperphenidol 
and amiloride and several other cationic compounds, like trimethoprim, TEA, and 
the H2-receptor antagonists ranitidine, nizatidine and famotidine were able to inhibit 
Cimetidine uptake partially, but significantly. The endogenous organic cation, n-
methylnicotinamide (NMN), decreased Cimetidine uptake also, whereas choline and 
guanidine did not. 
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Figure 2. Effect of increasing osmotic pressure on uptake at 30 min of 20 uM [3H]-cimetidine into 
SMMV. Vesicles were suspended in 300 mM mannitol and 10 mM Hepes-Tris, pH=7.4. 
Extravesicular media consisted of 10 mM Hepes-Tris, pH=7.4 and increasing concentrations of 
mannitol. Values of three placentas are expressed individually as pmol/mg protein versus reciprocal 
osmolality of the final solution (N=3). 
Table 2. Effect of various organic cations on Cimetidine uptake 
Organic cation 
control 
mepiperphenidol 
amiloride 
trimethoprim 
ranitidine 
famotidine 
nizatidine 
tetraethylammonium 
N-methylnicotinamide 
guanidine 
choline 
mM 
5 
% uptake 
100 
55 
85 
76 
54 
74 
69 
67 
71 
74 
100 
102 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
19 * 
2 
15 * 
20 * 
13 * 
12 * 
14 * 
10 * 
16 * 
2 
5 
Effect of various organic cations (1 or 5 mM) on the 30 sec uptake of 
20 uM [3H]-cimetidine in the presence of an outwardly directed H*-
gradient. Experimental conditions were similar to those given in the 
legend of Figure 1. Results are expressed relative to representative 
control uptakes (N=4). Mean control uptake was 112 ± 30 pmol/mg 
protein (N=10). * P<0.05. 
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Kinetics of Cimetidine uptake 
The presence of mediated uptake was further investigated by evaluating the 
initial uptake of increasing concentrations of Cimetidine in the presence of an 
outwardly directed H+-gradient. The relation between Cimetidine concentration and 
uptake rate was nonlinear. Total uptake corrected for estimated nonsaturable uptake 
showed saturability as can be seen in Figure. 3. Kinetic parameters were determined 
by fitting an euation combining Michaelis-Menten and linear kinetics: 
=
 т ш
· S / (!£„,+ S) + к · S to the data, where ν is the initial Cimetidine uptake 
rate and S is the Cimetidine concentration. Nonlinear regression analysis revealed a 
K,,, of 6.3 ± 4.4 mM, a V
m
„ of 17.5 ± 10.2 nmol/mg/10 sec and а к of 1.6 ± 0.3 
nmol/mg/1 Osec/mM. 
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Figure 3. Concentration-dependent uptake of [3H]-cimetidine at 10 sec into SMMV in the presence 
of an outwardly directed H+-gradient. Experimental conditions were the same as described in the 
legend of Figure 1. Cimetidine concentrations ranged from 10 uM to 20 mM. Values are 
expressed as nmol/mg protein (N=3). 
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Discussion 
In human in vivo studies and in the artificially perfused human placental 
cotyledon, no evidence was found for mediated transport of Cimetidine (Howe et al., 
1981, Ching et al., 1987). It was concluded that transfer of Cimetidine across the 
human placental trophoblast occurs by passive diffusion. However, if diffusional 
transfer quantitatively exceeds uptake via a mediated pathway, the latter will be 
masked and not detected in these type of studies. Therefore, isolated membrane 
vesicles are a more appropriate tool to investigate whether mediated transport 
occurs across the plasma membrane. 
Our results in human placental SMMV show that Cimetidine transfer across 
the syncytial microvillus membrane of the human term placenta will be mainly due 
to passive diffusion, confirming the results obtained by others (Howe et al., 1981, 
Ching et al., 1987, Schenker et al., 1987). However, a small, but significant part of 
total Cimetidine uptake into SMMV could be attributed to mediated uptake, since 
uptake was pH-dependent, inhibitable by several organic cations and saturable. 
Because the proton ionophore, FCCP, decreased H+-gradient-dependent Cimetidine 
peak uptake under voltage clamped conditions, we suggest the presence of an 
organic cation-proton antiport system for Cimetidine in human placental SMMV, 
responsible for the small part of mediated uptake. Cimetidine itself has been 
reported to interfere with the human placental Na7H+-exchanger present in the 
syncytial microvillus membrane, in a reversible manner and competitive with 
respect to Na+ (Ganapathy et al., 1986). It seems possible that Cimetidine, in the 
presence of a H+-gradient, is transported by this Na7H+-exchanger. The inhibition of 
Cimetidine uptake we observed in presence of the Na7H+-exchange inhibitor 
amiloride would support such a view. However, this cationic drug is not a selective 
inhibitor, because it also inhibits organic cation transport in human placental and 
rabbit renal cortical brush-border membrane vesicles (Ganapathy et al., 1988, 
Miyamoto et al., 1989). The inhibition of guanidine uptake into renal cortical brush-
border membrane vesicles by Cimetidine (Miyamoto et al., 1989) has not been 
found in human placental brush-border membrane vesicles (Ganapathy et al., 1988). 
Since guanidine did not inhibit Cimetidine uptake significantly in our experiments, 
the guanidine analogue Cimetidine is not likely to be transported by the guanidine-
proton antiport system present in human placental SMMV (Ganapathy et al., 1988). 
Cimetidine did inhibit membrane potential-dependent choline uptake into SMMV 
(van der Aa et al., 1994). In contrast, choline was not able to inhibit Cimetidine 
uptake significantly in the present study. Therefore it is also unlikely that Cimetidine 
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is transported by the choline carrier. 
The affinity of the system is low, as can be concluded from a K,,, of 6.3 mM 
characterizing the concentration-dependent uptake of Cimetidine. The clinical 
relevance of this low affinity system with respect to the use of H2-receptor 
antagonists during pregnancy seems therefore limited in terms of a possible 
accumulation into the trophoblast or extensive elimination from fetal to maternal 
circulation. Such a low affinity transport system in microvillus membranes would 
only make sense in combination with a high affinity system in basal membranes. 
From in vivo and perfused cotyledon experiments no evidence is available for the 
presence of such a system (Howe et al., 1981, Schenker et al., 1987). 
We therefore conclude that the system cannot be an important factor in the 
barrier function of the human placenta in the transport of Cimetidine as observed by 
Ching et al. (1987). Thus, active transport can indeed be ruled out in maintaining 
such a barrier. Other factors, as for instance the degree of ionization of Cimetidine 
(pKa=6.8) at physiological pH, are probably of more importance to the low 
clearance of Cimetidine across the human placental trophoblast. 
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Summary 
The uptake of the quaternary ammonium compound choline was studied in 
syncytial microvillous membrane vesicles of human term placenta. Uptake was 
stimulated by an inside negative membrane potential and by loading the vesicles 
with unlabelled choline. Imposition of an inwardly directed Na+- or outwardly 
directed H+-gradient did not result in a stimulation of choline uptake. Several 
organic cations were able to inhibit choline transport: hemicholinium-3 > choline £ 
mepiperphenidol > Cimetidine > famotidine. The kinetics of uptake involved a 
saturable process for choline with high affinity (!£„= 550 uM). 
Our results confirm the presence of a carrier mediated transport system in 
human placental syncytial microvillous membranes. The system appears to be 
electrogenic, and able to transport choline efficiently from the maternal circulation 
into the placenta driven by the negative cell interior. 
Introduction 
The cationic quaternary ammonium compound choline is an essential 
substrate for the synthesis of phospholipids and acetylcholine. Since the placenta 
and fetus do not synthesize choline, it must be transported from the maternal plasma 
by the trophoblast (Welsch, 1978). The human placental concentration of choline is 
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approximately 1 mM, whereas maternal plasma contains about 20 μΜ choline. 
Accumulated choline against this concentration gradient is rapidly converted into 
acetylcholine (Welsch, 1976). Although acetylcholine is present in large 
concentrations in the human placenta its main function, in an organ which lacks 
innervation, remains still unclear. It has been proposed that the placental cholinergic 
system plays a role in the regulation of amino acid transport ( Rowell and Sastry, 
1981). 
The mechanisms of choline transport have been characterized in various 
tissues. In neural tissue a high affinity sodium cotransport system has been 
described (Kuhar and Murin, 1978). In erythrocytes facilitated diffusion is involved, 
which is not sodium dependent (Deves and Krupka, 1979). In rat intestinal brush-
border membranes a choline transporter independent of sodium, H+ or membrane 
potential was found with a K,,, of 159 μΜ (Saitoh et al., 1992). Two saturable 
transport systems were found in rabbit renal brush-border membranes (1^= 97 μΜ 
and K
m
= 10 mM). Uptake was stimulated by an inside negative membrane potential 
and by a trans concentration gradient of choline Wright et al., 1992). 
The mechanism of choline transport across the placenta has still not been 
fully elucidated. In placenta fragments choline was concentrated against a 
concentration gradient. Nonsaturable passive diffusion in combination with carrier 
mediated transport was found, with K„= 350 μΜ and V
mM= 75 nmol/ml intracellular 
water/min (Welsch, 1978). Saturable sodium independent choline uptake into the 
trophoblast was demonstrated in the dually perfused guinea pig placenta (Sweiry et 
al., 1985) and human placenta (Sweiry et al., 1986). Nonsaturable components, 
reflecting passive diffusion, were also observed. Driving forces and specificity, 
however, of choline transport in the human placenta have still not been clarified. 
The present study was designed to provide more insight into the mechanisms 
of choline transport across the human placenta, using isolated syncytial microvillous 
membrane vesicles (SMMV) of human term placenta. 
Materials and methods 
Preparation of SMMV 
SMMV were prepared from fresh human term placentae, essentially 
according to a procedure by Glazier et al. (1988) described as method number three. 
Tissue was minced in a Warring blender. The mince was stirred for 30 min to 
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loosen the microvilli. After MgCl2 aggregation and differential centrifugation 
SMMV were harvested and suspended in an appropriate intravesicular buffer to a 
final protein concentration of 10-15 mg/ml. Vesicles were frozen in liquid nitrogen 
and stored at -80°C for four weeks at the maximum. The alkaline phosphatase 
enrichment, measured according to Mircheff and Wright (1976) of SMMV 
compared to starting mince was 24-fold (M0= 60 ± 7 and SMMV= 1400 ± 175 
umol/hr/mg, N=6). Protein was assayed with a coomassie blue kit (Biorad, 
München, Germany). 
Uptake studies 
Uptake of [3H]-choline into SMMV was measured in quadruplicate at 37 °C 
using a rapid filtration technique (Rüssel et al., 1988). The samples were filtered 
through Whatman GF/F filters and the radioactivity remaining on the filters was 
counted in a Beekman LS 6000 LL liquid scintillation counter. Corrections were 
made for nonspecific filter binding. Exact compositions of the transport conditions 
are given in the legends. Uptake is expressed as pmol or nmol/mg protein or % of 
control uptake (mean ± SD) of at least three experiments with three placentas. 
Paired Student's t-test was used to determine statistical significance (P<0.05). Curve 
fitting was done by least squares nonlinear regression analysis using the computer 
programme PCNONLIN (Metzler and Weiner, 1989). 
Chemicals 
[3H]-Choline was obtained from Amersham (Buckinghamshire, UK), 
Cimetidine from Smith, Kline & French (Welwyn Garden City, Herts, UK), and 
mepiperphenidol from Merck, Sharp & Dohme (Rahway, N.Y., USA). All other 
chemicals were purchased from either Sigma (St. Louis, M.O., USA) or Merck 
(Darmstadt, Germany) and were of analytical grade. GF/F filters were obtained 
from Whatman Int. Ltd. (Maidstone, England). 
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Results 
Time dependent uptake of choline 
The effect of an imposed gradient of H+ (pH,=6.0/pH
o
=7.4) and Na+ (100 
mM) on the uptake of 25 μΜ choline into SMMV is illustrated in Figure 1. An 
outwardly directed proton gradient did not stimulate the choline uptake (A). Neither 
did an inwardly directed sodium gradient (B). The effect of an inside negative 
membrane potential is shown in Figure 2. A stimulation of the uptake above 
equilibrium was observed (peak versus equilibrium^.8). 
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Figure 1. Effect of an outwardly directed proton gradient (A) and inwardly directed sodium 
gradient (B) on the uptake of 25 uM [3H]-cholme into SMMV A Vesicles were suspended in 100 
mM manmtol, 100 mM KCl and 10 mM Hepes-Tns, pH=7 4 or 10 mM Mes-Tns, pH=6 0 
Extravesicular medium consisted of 100 mM manmtol, 100 mM KCl and 10 mM Hepes-Tns, 
pH=7 4 В Vesicles were suspended in 100 mM manmtol, 100 mM KCl and 10 mM Hepes-Tns, 
pH=7 4 Extravesicular media consisted of 100 mM manmtol, 100 mM KCl or 100 mM NaCl and 
10 mM Hepes-Tns, pH=7 4 10 ul vesicles were added to 40 μΐ extravesicular medium Values are 
expressed as pmol/mg protein (mean ± SD) 
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Figure 2. Effect of an inside negative membrane potential on the uptake of 25 μΜ [}H]-choline 
into SMMV. Vesicles, suspended in 100 mM mannitol, 100 mM KCl and 10 mM Hepes-Tris, 
pH=7.4, were preequilibrated with 20 uM valinomycin at 37 °C. Extravesicular media consisted of 
100 mM mannitol, 100 mM KCl or 100 mM NaCl and 10 mM Hepes-Tris, pH=7.4. 10 μΐ vesicles 
were added to 40 μΐ extravesicular medium. Values are expressed as pmol/mg protein (mean ± 
SD). 
Counter transport of choline 
The effect of loading the vesicles with 5 mM unlabelled choline on the 
uptake of 250 μΜ choline into SMMV is shown in Figure 3. Voltage clamp 
conditions were maintained by adding valinomycin and equal concentrations of 
intra- and extravesicular K+. The outwardly directed choline gradient stimulated the 
choline uptake above equilibrium (peak versus equilibrium=2.1). 
90 
"u 
* J 
o 
«H 
"o 
в 
Он 
s—* 
U 
ев 
6000 
4000 
2 2000 
O N 
υ 
tí 
"θ 
о 
S шМ choline (trans) 
no gradient 
+ 
1 
90 
time (min) 
Figure 3. Effect of an outwardly directed gradient of S raM choline on the uptake of 250 uM [3H]-
choline into SMMV. Vesicles, suspended in 100 mM mannitol, 100 mM KCl and 10 mM Hepes-
Tris, pH=7.4, were, in case of the outwardly directed choline gradient, preequilibrated with 5 mM 
unlabelled choline at 37 °C. Control and with choline loaded vesicles were also preequilibrated 
with 20 μΜ valinomycin at 37°C. Extravesicular media consisted of 100 mM mannitol, 100 mM 
KCl, 20 μΜ valinomycin, 10 mM Hepes-Tris, pH=7.4 and unlabelled choline to achieve an 
extravesicular concentration of choline of 250 μΜ. 5 μΐ vesicles were added to 195 ul 
extravesicular medium. Values are expressed as pmol/mg protein (mean ± SD). 
Effect of different drugs on choline uptake 
Figure 4 shows the effect 5 mM of various drugs on the uptake of 250 μΜ 
choline into SMMV, loaded with 5 mM unlabelled choline. Voltage clamp 
conditions were maintained. The structure analogue hemicholinium (HC-3), choline 
itself and the organic cation transport inhibitor mepiperphenidol (mepi) reduced 
choline uptake by 85 %. Cationic drugs like Cimetidine (cim) and famotidine (fam) 
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were able to inhibit uptake by 50 %. Low-molecular weight organic cations like 
tetraethylammonium (TEA) and n-methylnicoünamide (NMN) showed no inhibitory 
potency, neither did the organic anion transport inhibitor probenecid. 
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Figure 4. Effect of 5 mM cis concentrations of organic cations and anions on the 10 sec uptake of 
250 μΜ [3H]-choline into SMMV in the presence of an outwardly directed gradient of 5 mM 
choline. Experimental conditions were the same as described in the legend of Figure 3, except that 
5 mM of specified organic drugs were added to the extravesicular media. Values are expressed as 
% of control uptake (mean ± SD). Control uptake (without inhibitor) was 3130 ± 515 pmol/mg 
protein. * Statistical significance (P<0.05; df=2). 
Kinetics of choline uptake 
Over a range of 125 μΜ to 5mM, saturability in the uptake of choline was 
seen in the presence of an outwardly directed 5 mM choline gradient (Figure 5). 
Uptake values were measured under voltage clamp conditions. The curve resulting 
from subtracting simple diffusion (that part of total uptake that could not be 
inhibited by extravesicular choline) from total uptake was analyzed according to 
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Michaelis-Menten kinetics. Least-squares nonlinear regression analysis revealed a 
K,,, of 550 ± 80 μΜ and a V
m
„ of 10.0 ± 0.49 nmoymg protein/10 sec (R2 = 0.995). 
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Figure 5. Concentration dependent uptake of choline at 10 sec into SMMV in the presence of an 
outwardly directed gradient of 5 mM choline with and without 20 mM choline in the extravesicular 
medium to saturate the carrier in order to determine the simple diffusion component of total 
uptake. Experimental conditions were the same as described in legend of Figure3. Uptakes were 
measured in the presence of increasing concentrations choline (0.12S-S mM). Values are expressed 
as nmol/mg protein (mean ± SD). 
Discussion 
Our results in SMMV, confirm the existence of an uphill mediated transport 
mechanism for choline in the human placenta. A transient accumulation of choline 
was seen in the presence of an outwardly directed choline gradient, which is 
considered to be indicative for carrier mediated transport. Uptake into SMMV was 
also stimulated above equilibrium uptake by an inside negative membrane potential. 
We conclude that the physiologically negative cell interior can act as a driving force 
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for placental choline uptake from the maternal circulation. The uptake into SMMV 
was sodium independent. This result is in good agreement with the sodium 
independent uptake into the trophoblast, as was demonstrated in the dually perfused 
guinea pig placenta (Sweiry et al., 1985). Choline transport in rabbit renal brash 
border membranes (Wright et al., 1992), human erythrocytes (Deves and Krupka, 
1979) and rat intestinal brash border membranes (Saitoh et al., 1992) is also sodium 
independent in contrast to the uptake in neural tissue, which is sodium coupled 
(Kuhar and Murin, 1978). It seems that a sodium gradient, maintained by Na7K+ 
ATPase, is not directly involved in choline transport in most tissues including the 
human placenta. 
Several cations were able to inhibit choline uptake at relatively high 
concentrations. The analogue HC-3, choline itself and the organic cation transport 
inhibitor mepiperphenidol inhibited the choline uptake nearly completely, whereas 
cationic drugs like Cimetidine and famotidine only partly reduced choline uptake. 
Therapeutic plasma concentrations of these H2-receptor antagonists are low, which 
means that the clinical relevance of this inhibition, at concentrations as high as 5 
mM, will be limited. NMN and the quaternary ammonium compound TEA did not 
inhibit the uptake. In rabbit renal brash-border membranes TEA also had no 
inhibitory potency (Wright et al, 1992), whereas in rat intestinal brash-border 
membranes TEA and NMN caused both cis-inhibition and trans-stimulation (Saitoh 
et al., 1992). Because of the strong inhibition of choline and HC-3 as compared to 
the other cations we suggest a relatively high specificity of the choline transporter 
in placental SMMV. Whereas our results indicate an affinity of cationic drugs for 
the choline carrier the reverse, an affinity of choline for the organic cation/proton 
antiporter for guanidine could not be determined in placental brush-border 
membranes (Ganapathy et al., 1988). In the same study Cimetidine did not inhibit 
this guanidine carrier. It seems that exogenous organic cations interfere with the 
choline transporter rather than with the guanidine transporter. 
The kinetics determined in SMMV involved a saturable process with a K,,, 
of 550 μΜ, corresponding with a value of 350 uM found in placental fragments 
(Welsch, 1976) and greater than 97 uM and 159 μΜ found in other epithelia like 
rabbit renal brush-border membranes (Wright et al., 1992) and rat intestinal brash-
border membranes (Saitoh et al., 1992), respectively. А К,,, of 550 μΜ, which is far 
above the maternal plasma concentration of 20 μΜ, assures an efficient uptake of 
choline into the trophoblast. 
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In conclusion, the transport system for choline in syncytial micovillous 
membrane vesicles of human term placenta demonstrated here, can efficiently 
provide for the placental uptake of choline from the maternal circulation driven by 
the negative cell interior. It is believed that this syncytial accumulation is essential 
for the permeability of the trophoblast for amino acids (Rowell and Sastry, 1981) or 
for the fetal need of choline. The apparent discrepancy between the low placental 
transfer as shown by Sweiry et al. (Sweiry et al., 1986) and the significant placental 
uptake of choline suggests that the placenta will function as a buffer for the fetal 
need of choline. Fetal choline uptake will therefore be regulated mainly by the 
transfer across the basal membrane of the trophoblast. 
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Summary 
The potency and nature of the inhibitory effect of various cationic drugs on 
the transport of choline across the placental syncytial microvillous membrane was 
investigated. TEA, a model substrate for organic cation transport, was a poor 
inhibitor. Enlarging the degree of alkylation of the quaternary ammonium increased 
the inhibitory effect, in proportion with increasing lipophilicity. Log concentration 
versus % control uptake curves showed marked differences in inhibitory potency for 
the different cationic drugs. HC-3 inhibited mediated choline uptake in the 
micromolar range, whereas atropine and mepiperphenidol were less potent. H2-
receptor antagonists Cimetidine, ranitidine and famotidine inhibited choline uptake in 
the millimolar ranges. Dixon analysis revealed a competitive nature of inhibition for 
HC-3 and atropine (K, = 40 μΜ and 1,2 mM, respectively). Cimetidine interacted 
noncompetitively (Kj = 3.4 mM). Since relatively high concentrations are needed to 
reach half maximal inhibition, impairment of fetal choline supply due to maternal 
drug use during pregnancy is not to be expected. 
Introduction 
Choline, a cationic quaternary ammonium compound, is an essential substrate 
for adequate growth and development of the fetus. Choline serves as a substrate for 
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the synthesis of phospholipids and acetylcholine. Since the human placenta and 
fetus do not synthesize choline, fetal supply is highly dependent on the proper 
transfer of this nutrient from materaal to fetal circulation (Welsch, 1976). The initial 
step in placental transfer involves uptake across the syncytial microvillous 
membrane of the trophoblast. In the perfused human placental cotyledon, trans-
placental transfer was slow in contrast to the fast and high placental uptake (Sweiry 
et al., 1986). Since there was a small excess of irans-placental choline transfer in 
comparison with the extracellular marker mannitol, preferentially towards the fetal 
circulation, the human placenta possesses a unidirectional pathway for choline in the 
maternal to fetal direction. Placental choline uptake on the maternal side was 
inhibited by choline itself and on the fetal side by HC-3, a well-known competitive 
inhibitor of the choline transporter in various tissues, suggesting the existence of a 
specific transport systems at both sides of the trophoblast. Evidence for mediated 
trophoblastic choline uptake was also found in human placental fragments, which 
accumulated choline against a concentration gradient inhibitable by HC-3 with a K¡ 
of 0.45 mM. However, because uptake in fragments is the net result of transport 
across both the syncytial microvillous and basal membranes, it is impossible to 
differentiate between inhibition of the choline transporter at both sides of the 
trophoblast. Isolated vesicles of these membranes are a more appropriate tool for 
investigating the location and nature of such interactions. Recently, we described 
the mechanisms of choline uptake into isolated syncytial microvillous membrane 
vesicles of human term placenta (van der Aa et al., 1994). Uptake was not sodium-
dependent or coupled to proton transport. An inside negative membrane potential 
enhanced choline uptake, showing that a negatively charged inner membrane surface 
acts as a driving force for trophoblastic choline uptake. Mediated transport was 
confirmed by the trans-stimulatory effect of unlabeled choline and cis-inhibitory 
effect of HC-3, the organic cation transport inhibitor mepiperphenidol and H2-
receptor antagonists. Model substrates for organic cation transport TEA and NMN 
did not inhibit choline transport. Furthermore, we found that uptake under trans-
stimulation conditions was saturable with a K,,, of 550 μΜ. Our results were 
confirmed in a study by Grassi, who used exactly the same approach (Grassi, 1994). 
In addition he showed on the basis of evaluation of the inhibitory potency of a great 
amount of organic cations that at least two sites of interaction with the choline 
transporter can be postulated: a negative site that binds with the positively-charged 
nitrogen and a site of hydrogen bonding that interacts with the primary alcohol. 
Furthermore, the degree of nitrogen group alkylation appeared to be of importance. 
Since trophoblastic uptake is the rate-limiting step in fetal choline supply, 
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interaction of maternally-administered drugs with the choline transporter at the 
microvillous membrane could have clinical implications for fetal growth and 
development. This study was designed to further investigate the specificity of the 
choline transporter at the syncytial microvillous membrane of the human placental 
trophoblast, by characterizing the inhibitory potency and nature of the interaction of 
various cationic drugs. 
Materials and methods 
Chemicals 
[3H]-Choline was obtained from Amersham (Buckinghamshire, U.K.). 
Cimetidine was kindly donated by Smith, Kline & French (Welwyn Garden City, 
Herts, U.K.) and mepiperphenidol and famotidine by Merck, Sharp & Dohme 
(Rahway, NJ, U.S.A.). All other chemicals were purchased from either Sigma (St. 
Louis, MO, U.S.A.), Merck (Darmstadt, Germany) or Boehringer Mannheim 
(Mannheim, Germany) and were of analytical grade. GF/F filters were obtained 
from Whatman Int. Ltd. (Maidstone, U.K.). 
Preparation of SMMV 
SMMV were prepared from fresh human term placentae according to an 
established (Glazier et al., 1988), which was further improved upon our laboratory 
(van der Aa et al., 1994; van der Aa et al., in press). Briefly, tissue was minced in a 
Warring blender and stirred for 30 min to loosen the microvilli. After MgCl2 
aggregation and differential centrifugation SMMV were harvested and suspended in 
the appropriate intravesicular buffer for uptake studies, to a final protein 
concentration of 10-15 mg/mL. Vesicles were frozen in liquid nitrogen and stored at 
-80°C for four weeks at the maximum. This freezing and storage procedure did not 
influence choline uptake. The alkaline phosphatase enrichment of SMMV, measured 
according to Mircheff and Wright (1976), was 24-fold (Mo = 70 ± 15 and SMMV = 
1690 ±310 umol/hr/mg, N=14) compared to starting mince. Protein was assayed 
with a Coomassie blue kit (Biorad, Munich, Germany). 
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Uptake studies 
Uptake of [3H]-choline into SMMV was measured in quadruplicate at 37 °C 
using a rapid filtration technique (Rüssel et al., 1988). The samples were filtered 
through Whatman GF/F filters (average pore size 0.7 urn) and the radioactivity 
remaining on the filters counted in a Beekman LS 6000 LL liquid scintillation 
counter. Corrections were made for nonspecific filter binding. The exact conditions 
of the transport experiments are given in the legends. Uptake is expressed as pmol 
or nmol/mg protein or % of control uptake (mean ± SD), N representing the number 
of experiments with different placentae. 
Data analysis 
From concentration versus % uptake curves of 3 concentrations of choline 
below Km (50, 125 and 250 uM), the concentration required to reach half maximal 
inhibition (IC50) of several cationic drugs was estimated by least squares nonlinear 
regression analysis, using the computer program GraphPad Inplot 4.0 (1992). The 
weighted residual sums of squares of one- and two-site models were compared 
using the F-test. Transformation of the data according to Dixon (1953) revealed the 
nature of inhibition. The inhibitory constant (K¡) for a competitive inhibitor was 
estimated according to the equation of Cheng-Prusoff: Kj = IC^, / 1+(S/Km), where 
S = choline concentration (1973). For K,,, and Vm„ of choline previously determined 
values were used viz. 550 uM and 10 nmol/mg/10 sec, respectively (van der Aa et 
al., 1994). In case of a noncompetitive inhibitor, IC50 is independent of S, and 
consequenüy K¡ equals IC50. Paired Student's t-test was used to determine statistical 
significance (P < 0.05). 
Results 
Inhibitory potency tetraalkylammonium compounds 
In our previous study it was found that 5 mM TEA did not inhibit choline 
(250 uM) uptake into SMMV (van der Aa et al., 1994). We now investigated 
whether variation in the degree of alkylation of TEA influences inhibitory potency. 
Enlarging the alkyl chains at the quaternary ammonium resulted in a higher 
percentage of inhibition (Figure 1). The increase in inhibitory potency of the 
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compounds corresponded well with the increase in lipophilicity as given by their 
calculated log Ρ values (Wright et al., 1995). Because of the surface tension 
lowering properties of the tetraalkylammonium compounds, we verified whether the 
vesicles stayed intact in the presence of the inhibitors. Only in the presence of THA 
was the equilibrium uptake of 250 μΜ choline at 60 min significantly reduced as 
compared with control uptake. The other compounds did not interfere with the 
membrane integrity. 
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Figue 1. Effect of 1 mM cis concentrations of a series of homologous quaternary ammonium 
compounds on uptake of 250 μΜ [3H]-choline at 10 sec. Vesicles, suspended in 100 mM mannitol, 
100 mM KCl and 10 mM Hepes-Tris, pH=7.4, were pre-equilibrated with 5 mM unlabeled choline 
and 20 μΜ valinomycin at 37°C. 5 цЬ vesicle suspension was added to 195 uL extravesicular 
medium. Extravesicular media consisted of 100 mM mannitol, 100 mM KCl, 20 μΜ valinomycin, 
10 mM Hepes-Tris, pH=7.4, inhibitor at a specified concentration and unlabeled choline to achieve 
an extravesicular concentration of 250 μΜ in the final solution. Values are expressed as % of 
representative control (without inhibitor) uptakes (mean ± SD, N=3). Control uptake was 5115 ± 
625 pmol/mg protein. *P<0.05. 
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Figure 2. Inhibiton of 250 μΜ [3H]-choIine uptake into SMMV at 10 sec under trans-stimulation 
conditions by various organic cations. Experimental conditions were the same as described in 
legend of Figure 1. Values are expressed as % of representative control uptakes versus log 
concentration inhibitor (mM). Each point represents the mean ± SD of three experiments with three 
placentae, except for famotidine and TEA (N=1). 
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Inhibition of choline uptake by several organic cations 
Plots of log concentration inhibitor versus % of control uptake of 250 μΜ 
choline are shown in Figure 2. The results of the nonlinear regression analysis of 
the typically sigmoid shaped curves are summarized in Table 1. Marked differences 
in inhibitory potency can be seen between the organic cations tested. HC-3 inhibited 
choline uptake for 50 % at a relatively low concentration, whereas the organic 
cation transport inhibitor mepiperphenidol and the anticholinergic drug atropine 
were less potent inhibitors. The H2-receptor antagonists Cimetidine, ranitidine and 
famotidine showed IC^, values only in the mM ranges. For TEA only a rough 
estimate of the IC50 value could be made, because of the very high concentrations 
(> 10 mM) necessary to achieve half maximal inhibition. In all cases analysis 
according to a two-site model did not fit the data better than a one-site model 
(P>0.2). 
Table 1. Apparent inhibitory constants of cationic drugs on choline 
uptake. 
Compound 
choline 
HC-3 
atropine 
mepiperphenid 
Cimetidine 
ranitidine 
famotidine 
TEA 
ІСя (mM) 
0.55 ±0.11 
0.069 ± 0.004 
1.45 ±0.30 
0.85 ± 0.55 
3.39 ± 0.47 
4.04 ± 0.62 
3.80 (N=1) 
>50 (N=1) 
Κ,(ΓΠΜ) 
-
0.039 ± 0.009 " 
1.24 ±0.10 " 
-
3.39 ± 0.47 " 
-
-
-
ICJO values determined from inhibition curves at a choline 
concentration of 250 μΜ and inhibitory constants K, (a: competitive; 
b: noncompetitive) determined from inhibition curves at 50, 125 and 
250 uM choline. Values are expressed as means ± SD, N=3, except 
for famotidine and TEA. 
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Figure 3. Dixon plots of interaction of HC-3, atropine and Cimetidine with choline. Concentrations 
of extravesicular [3H]-choline were 50, 125, 250 μΜ. Experimental conditions were the same as 
described in legend of Figure 1, except that in the case of 50 μΜ choline 5 \iL vesicle suspension 
was added to 495 uL extravesicular medium. 
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Nature of interaction with the choline transporter 
Although ICJO values provide a good measure of inhibitory potency they 
cannot explain the nature of the interaction. We used the method of Dixon analysis 
to evaluate the type of choline transport inhibition by HC-3, atropine and 
Cimetidine. The concentration-dependent inhibition of these compounds was 
measured at three choline concentrations: 50, 125 and 250 μΜ. Increasing the 
substrate concentration decreased the inhibitory effectiveness of HC-3 and atropine, 
resulting in a lower IC^, value at a lower choline concentration. Transformation of 
the data according to Dixon showed that the lines intersected above the X-axis and 
to the left of the Y-axis, indicating a competitive mode of interaction of HC-3 and 
atropine with the choline transporter (Figure 3). K, values for competitive inhibition, 
calculated from the Cheng-Prusoff equation for the three choline concentrations, 
were 40 uM for HC-3 and 1.2 mM for atropine (Table 1). In contrast, the IC50 value 
for Cimetidine was independent of the choline concentration. Dixon analysis resulted 
in an intersection of the lines on the X-axis, consistent with a noncompetitive type 
of interaction (Figure 3). Consequently the K, for Cimetidine equalled the IC^ 
value of 3.4 mM (Table 1). 
Discussion 
The present study demonstrates that several cationic drugs inhibited human 
placental choline transport across the syncytial microvillous membrane with 
different inhibitory potencies. HC-3 and atropine appeared to be competitive 
inhibitors, whereas Cimetidine interacted noncompetitively. TEA, a model substrate 
for organic cation transport in various tissues, only inhibited choline transport at 
very high concentrations. Enlarging the degree of alkylation of this quaternary 
ammonium compound increased the inhibitory effect in proportion with increasing 
lipophilicity. 
Wright et al. (1992) postulated a set of structural elements important for 
interaction with the choline transporter: (a) a terminal hydroxyl group; (b) the 
positive charge of the nitrogen; and (c) the presence of at least two free methyl 
groups at the positive nitrogen. The placental choline transporter appeared to have a 
similar substrate specificity (Grassi, 1994). Small quaternary ammonium compounds 
such as TMA, acethylcholine and NMN showed affinity for the rat intestinal choline 
carrier (Saitoh et al., 1992), whereas TMA showed no affinity for the human 
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placental (Grassi, 1994) and rabbit renal choline transporter (Wright et al., 1992). 
The inability of large molecular quaternary ammonium compounds to interact with 
the choline transporter was assumed to be due to steric hindrance, viz., the masking 
of the positive nitrogen (Wright et al., 1992; Saitoh et al., 1992). The failure of 
TEA, for instance, to interact with the choline transporter was further confirmed by 
the finding that TEA was not able to trans-stimulate choline uptake into renal and 
intestinal brush-border membrane vesicles (Wright et al., 1992; Saitoh et al., 1992; 
Takano et al., 1993). In the present study TMA, TEA and TPrA did not or poorly 
inhibited placental choline transport. In spite of lack of determinants important for 
interaction with the choline transporter, further enlargement of the alkyl chains 
resulted in a significant inhibition of placental choline transport by TBA, TPeA and 
THA. For TPeA this was also observed in rabbit renal brush-border membranes 
(Wright et al., 1992), and in the study by Grassi (1994) a higher degree of 
inhibition of choline uptake was found in the presence of trimethylphenyl-
ammonium as compared to no significant inhibition with TMA. The reduced 
choline uptake in the presence of the more lipophylic quaternary ammonium 
compounds is likely to be of noncompetitive nature (Naujokatis et al., 1982). The 
higher degree of alkylation probably facilitates a nonspecific interaction, e.g. 
solubilization into the membrane or interaction with an allosteric binding site at the 
transport protein, thereby interfering with the ability of the carrier to transport 
choline. 
Cimetidine has affinity for the cation-proton antiporter (Takano et al., 1993), 
but to our knowledge no data concerning a possible interaction with the choline 
transporter are currently available. However, in renal brush-border membranes an 
affinity of choline for the organic cation-proton antiporter has been demonstrated, 
since choline inhibited TEA transport (Wright and Wunz, 1989; Miyamoto et al., 
1989). Our data provide evidence that H2-receptor antagonists inhibit choline uptake 
noncompetitively. The measured IC50 values were in the mM range and inhibitory 
potency of Cimetidine was not dependent on choline concentration, resulting in an 
intersection of lines on the abscissa after Dixon transformation. It therefore seems 
unlikely that clinically significant interactions of these drugs with choline uptake in 
vivo will occur. Cimetidine is the highest dosed H2-receptor antagonist, but maternal 
effective plasma concentrations (90 % inhibition of gastric acid production) are only 
approximately 15 μΜ (Somogyi and Gugler, 1983). For the lower dosed drugs, 
famotidine and ranitidine, IC50 values in the same range as for Cimetidine were 
observed. Significant interactions in vivo of these nowadays more frequently 
prescribed H2-receptor antagonists are therefore not to be expected. 
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The different IC50 values of HC-3 at different choline concentrations indicate 
that the inhibitory potency of HC-3 was dependent on choline concentration. The 
same pattern of inhibition was found for atropine, which is indicative of a 
competitive interaction. HC-3 is an effective inhibitor, as its affinity for the choline 
transprter was more than 10-fold higher than for choline itself (K, for HC-3= 40 uM 
and K
m
 for choline= 550 μΜ), whereas the affinity for atropine was more than 2-
fold lower (K= 1.2 raM). The Y-coordinates of the intersections in the Dixon plot 
(HC-3= 0.12, atropine= 0.07) corresponded well with the 1/
 т и
 value of 0.10, 
providing further conformation that both inhibitors indeed interacted competitively 
(Wright and Wunz, 1989). Although Grassi did not report a K, value for HC-3, a 
value of 92 μΜ can be calculated from his data (Grassi, 1994). In human placental 
fragments a K, of 450 μΜ for HC-3 was reported (Welsch, 1976), which is almost 
10-fold higher than the value we estimated in isolated human placental SMMV. 
This discrepancy is most likely due to the different experimental techniques used. 
An inhibition constant determined in fragments is merely a hybrid parameter from 
interaction with choline transporters at the microvillous and basal side of the 
trophoblast, whereas the inhibitory effect in purified microvillous membranes can 
only be ascribed to an interaction with the choline transporter at this membrane. 
Therefore estimating inhibitory parameters of drugs on transport proteins is more 
appropriate in purified membranes. However, the net effect on the transfer of 
choline in maternal to fetal direction should be determined in more physiologically-
based models such trophoblast cell culture or cotyledon perfusion models. 
We conclude that several cationic drugs are able to interact with human 
placental choline transport across the syncytial microvillous membrane in a 
competitive and noncompetitive way. Competitive inhibition was seen in the μΜ 
and low mM ranges, whereas noncompetitive inhibition was seen in the high mM 
ranges, indicating a nonspecific interaction with the biomembrane. Since relatively 
high concentrations were needed to reach half maximal inhibition, impairment of 
fetal choline supply in vivo due to maternal drug use during pregnancy is not to be 
expected. 
Acknowledgements 
We are grateful to the Department of Gynaecology and Obstetrics, University Hospital St. 
Radboud, Nijmegen for their assistance in obtaining placentae. These investigations were supported 
by the Netherlands Organization for Scientific Research (NWO). 
108 
References 
Van der Aa E.M., Wouterse A.C., Copius Peereboom-Stegeman J.H.J, and Rüssel F.G.M. (1994) 
Uptake of choline into syncytial microvillus membrane vesicles of human term placenta. 
Biochemical Pharmacology 47, 453-456. 
van der Aa E.M., Copius Peereboom-Stegeman J.H.J, and Rüssel F.G.M., Isolation of syncytial 
microvillous membrane vesicles from human term placenta and their application in drug-
nutrient interaction studies. Journal of Pharmacological and Toxicological Methods, in 
press 
Cheng Y-C. and Prusoff W.H. (1973) Relationship between the inhibition constant (K,) and the 
concentration of inhibitor which causes 50 per cent inhibition (ICW) of an enzymatic 
reaction. Biochemical Pharmacology 22, 3099-3108. 
Dixon M. (1953) The determination of enzyme inhibitor constants. Biochemical Journal 55, 170-
171. 
Glazier J.D., Jones C.J.P. and Sibley C.P. (1988) Purification and Na+ uptake by human placental 
microvillous membrane vesicles prepared by three different methods. Biochimica 
Biophysica Acta 945, 127-134. 
GraphPad Inplot 4.0 (1992) Scientific graphics and curve fitting. GraphPad Software Ine, San 
Diego, USA. 
Grassi S.M. (1994) Choline transport in human placental brush-border membrane vesicles. 
Biochimica Biophysica Acta 1194, 203-213. 
Mircheff A.K. and Wright E.M. (1976) Analytical isolation of plasma membranes of intestinal 
epithelial cells: identification of NaVK^-ATPase rich membranes and the distribution of 
enzyme activities. Journal of Membrane Biology 28, 309-337. 
Miyamoto Y., Tiruppathi C , Ganapathy V. and Leibach F. (1989) Multiple transport systems for 
organic cations in renal brush-border membrane vesicles. American Journal of Physiology 
256, F540-F548. 
Naujokatis S.A., Fisher J.M. and Rabinovitz M. (1982) Tetraalkylammonium ions: Protection of 
murine L1210 leukemia and bone marrow progenitor cells in vitro against mechlorethamine 
cytotoxicity and inhibition of the choline transport system. Chemical Biology Interactions 
40, 133-140. 
Rüssel F.G.M., van der Linden P.E.M., Vermeulen W.G., Heijn M., van Os C.H. and van 
Ginneken C.A.M. (1988) Na* and H+ gradient dependent transport of p-aminohippurate in 
membrane vesicles from dog kidney cortex. Biochemical Pharmacology 37, 2639-2649. 
Saitoh H., Kobayashi M., Iseki K. and Miyazaki К. (1992) Carrier-mediated transport systems for 
choline and its related ammonium compounds on rat intestinal brush-border membrane. 
Biocimica Biophysica Acta 1112, 153-160. 
Somogyi A. and Gugler R. (1983) Clinical pharmacokinetics of Cimetidine. Clinical 
Pharmacokinetics 8, 463-495. 
Interaction with placental choline transport 109 
Sweiry J.H., Page K.R., Dacke C.G., Abramovich D.R. and Yudilevich D.L. (1986) Evidence of 
saturable uptake mechanisms at maternal and fetal sides of the perfused human placenta by 
rapid paired-tracer dilution: studies with calcium and choline. Journal of Developmental 
Physiology 8, 435-445. 
Takano M., Inui K-I., Окало T. and Hon R. (1985) Cimetidine transport in rat renal brush-border 
and basolateral membrane vesicles. Ufe Science 37, 1579-1585. 
Takano M., Katsura T., Tomita Y., Yasuhara M. and Hori R. (1993) Transport mechanism of 
choline in rat renal brush-border membrane. Biological Pharmceutical Bulletin 16, 889-
894. 
Welsch F. (1976) Studies on accumulation and metabolic fate of (N-Me3H]choline in human term 
placental fragments Biochemical Pharmacology 25, 1021-1030. 
Wright S.H. and Wunz T.M. (1989) Amiloride transport in rabbit renal brush-border membrane 
vesicles. American Journal of Physiology 256, F462-F468. 
Wright S.H., Wunz T.M. and Wunz T.R (1995) Structure and interaction of inhibitors with the 
TEA/H* exchanger of rabbit renal brush border membranes. Pflüglers Archives-European 
Journal of Physiology 429, 313-324. 
Wright S.H., Wunz T.M. and Wunz T.R (1992) A choline transporter in renal brush-border 
membrane vesicles: energetics and structural specificity. Journal of Membrane Biology 
126, 51-56. 

PART III 
DRUG TRANSFER ACROSS THE ISOLATED 
DUALLY PERFUSED COTYLEDON 

Chapter 7 
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Summary 
A dual perfusion system of the isolated cotyledon of human term placenta 
has been validated, in order to study placental drug transfer and metabolism. The 
recirculating (closed) perfusion system showed a good diffusibility, since the 
disappearance of antipyrine from the maternal circulation (CL = 2.33 ml/min) and 
concomitant rise in the fetal circulation, was comparable to literature. In contrast to 
antipyrine, the hydrophylic, membrane impermeable compound inulin did cross the 
placenta for only approximately 6 %, indicating the integrity of the membrane 
barrier. Metabolic viability of the preparation was maintained, since a net 
glucoseflactate conversion was observed. We conclude that our system is suitable 
for placental drug transfer and metabolism studies. 
Introduction 
Tissue cultures (Bullen et al., 1990), fragments (Welsch, 1976) and 
membrane vesicles (Smith et al., 1974; Kelley et al., 1983) of human term placenta 
have contributed greatly to the understanding of mechanisms of solute transport 
across the human placenta. However, for the investigation of overall transfer and 
the preferential direction of transport - towards the mother or towards the fetus -
these techniques are not adequate enough. 
In human, examination of placental transport processes is practically 
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impossible without severe risks for the developing fetus. Although animal studies 
have been used (Faber et al., 1992), preference has to be given to human data, 
because of the major interspecies differences in placental transport function (Page, 
1993). Studies with human term placenta can overcome the extrapolation problem 
of animal to human data. 
Attempts have been made to mimic the human in vivo situation by perfusing 
the whole placenta in vitro (Vermeulen, 1982; Wiegand, 1984). Since a whole 
placenta, completely free of major damage, is rare, this technique is difficult to 
perform. An alternative has been developed by Schneider and co-workers (1972), in 
which a single cotyledon of human term placenta is dually perfused. The advantages 
of this technique are obvious: the ability to select a suitable, undamaged cotyledon, 
the possibility to examine placental transfer in both directions and performing 
perfusions under steady-state conditions in a single pass mode or in a recirculating 
mode for drugs with a low extraction rate. Nowadays, this technique is widely used 
and modifications to improve its utility, resulting in a higher interexperimental 
consistency, have been described (Schneider and Huch, 1985; Brandes et al., 1983; 
Penfold et al., 1981; Contractor and Stannard, 1983). 
In this chapter we describe the system, preparation method and viability of 
the dually perfused isolated cotyledon of human term placenta, which was set up in 
our laboratory based on the method of Schneider et al. (1972, 1985). 
Materials and Methods 
Perfusion system and preparation 
Human term placentae, with clamped umbilical cord, were brought to our 
laboratory in 0.9 % NaCl (4°C), immediately after vaginal or caesarian delivery. 
After careful examination, a periferal cotyledon was selected suitable for dual 
perfusion. The arterial and venous chorionic vessels were canulated with metal 
cannulae (outer diameter: 2 mm and 3 mm, respectively), connected to a short 
silicon tube as an intermediate to 02 -impermeable, TEFLON-tubing (inner 
diameter: 1.9 mm) in the rest of the perfusion system. The fetal arterial inflow 
(37°C) was started at 0.15 ml/min and gradually increased to 6 mUmin by perfusion 
pump 1 (MS-1 reglo/6-160, Ismatic, Zürich, Switserland). Proper connection of the 
fetal artery to the vein was checked by verifying that the fetal venous outflow 
equalled the fetal arterial inflow. The fetally perfused cotyledon was fixed in a 
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perspex ring and placed into the perfusion chamber (37°C) with the maternal 
surface faced upwards. The intervillous space, connected to the fetally perfused 
region, was perfused by four small metal cannulae (outer diameter: 1 mm), which 
were inserted by pressing them gently through the decidual plate. The maternal 
inflow was gradually increased to 12 ml/min by the second perfusion pump. The 
perfusate returning through the intervillous openings was continuously drained by 
the third perfusion pump. Fetal arterial perfusion pressure (TDNR transducer, Viggo 
Spectramed, Oxnard, CA, USA), perfusate pH (PHM 92 LABpH meter and 
GK2401C pH electrode, Radiometer Copenhagen, Bagsvaerd, Danmark), 
temperature (Thermo-probe, New Port Electronics, Amstelveen, the Netherlands) 
and p 0 2 (Mini dark electrode 730, Diamond General dev. cor., Ann Arbor, MI, 
U.S.A.) and venous perfusion pressure and perfusate p0 2 , were continuously 
monitored and stored in a computer using the program POLY (Inspector Research 
Systems, Amsterdam, the Netherlands). Similarly, maternal arterial perfusate 
temperature, pH and p 0 2 were monitored throughout the experiment. Figure 1 
shows a scheme of the perfusion system described above. 
Chemicals 
Maternal and fetal perfusates were of the following composition (mM): NaCl 
(112.0), KCl (5.2), NaHCOj (20.2) KH 2P0 4 (0.3), Na^PO,, (0.9), CaCl2 (2.0), 
MgCl2 (1.0), glucose (5.0), to which 2500 IU/1 heparin, 2% bovine serum albumin, 
1% dextran 40 and 1 % Synthamin 14 (a mixture of 15 amino acids) were added. 
The perfusates were equilibrated with 95% 0 2 and 5% C 0 2 and together with the 
20.2 mM NaHC0 3 added in the perfusates, pH was buffered to 7.3-7.5. 
Bovine serum albumin Fraction V was obtained from Boehringer Mannheim 
(Mannheim, Germany), heparin (TromboliquinR, 5000 Ш/1) was purchased from 
Organon Teknika (Boxtel, the Netherlands) and Synthamin 14 (without electrolytes) 
from Travenol Laboratories Ltd. (Norfolk U.K.). All other chemicals were obtained 
from either Sigma Chemical Co. (St. Louis, U.S.A.) or Merck (Darmstadt, 
Germany) and were of analytical grade. 
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Figure 1. Scheme of the dual perfused isolated cotyledon of human term placenta (m=maternal 
circuit and f=fetal circuit). 
Experimental design 
After cannulation, perfusion experiments were started in a 30 min single pass 
mode (pre-phase) on both sides, to let the cotyledon stabilize and recover from the 
period of anoxia and to clear the cotyledon from remaining blood. The test-phase of 
the experiment was then started by replacing the perfusion fluid in the reservoirs 
and changing to the recirculating mode by closing the circuits. The perfusion fluid 
(175 ml for each circulation) used in this phase were the same as described above, 
except that antipyrine (14.1 mg) was added to the maternal perfusate, in order to 
validate the diffusion permeability of the placenta. In two experiments inulin (26.1 
mg) was added to the maternal perfusate, to assess the integrity of the placenta. In 
these experiments dextran 40 was omitted from the perfusates, because of its 
interference with the inulin assay. During the pre- and test-phases volume loss from 
the reservoirs, indicative for flux into extra perfused tissue or defects in the 
placental barrier, were registered. When the volume loss, corrected for sampling 
volume, was more than 3 ml/h the experiment was terminated. Fetal inflow pressure 
was 21.5 ± 7.2 mm Hg. Since both reservoirs were equilibrated with carbogen no 
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net 0 2 transfer occurs and determination of p0 2 in these experiments was 
unnecessary. 
For determination of antipyrine, inulin, glucose and lactate concentrations, 
samples (2 ml) were taken from both reservoirs at every 5 min until 30 min and at 
45, 60, 90 and 120 min and centrifuged (10 min, 1500-G) to eliminate erythrocytes. 
Volume loss due to sampling was less than 15 %. After termination of the 
experiment the perfused cotyledon was excised, weighed and frozen until analysis. 
Analytical methods 
Antipyrine was measured colorimetrically according to the method described 
by Brodie et al. (1949) and inulin according to the method described by Heyrovski 
(1956). Glucose and lactate were measured enzymatically (D-Glucose-kit and D/L-
Lactic acid-kit, Boehringer Mannheim, Germany). 
Data analysis 
Pharmacokinetic analysis of placental antipyrine transfer was done by fitting 
the antipyrine maternal and fetal concentration data to equations 1 and 2, using the 
computer program PCNONLIN (Metzler and Weiner, 1989), where Cm and Cf are 
maternal and fetal concentrations, C0 is the initial maternal concentration a, and a^ 
are first-order rate constants, C,^,
 m and C^,,, f are maternal and fetal concentrations 
at equilibrium: 
Cf - Cgqui,f ' 0 ~e )
 ( 2) 
Placental clearance (CL) was calculated as D/AUCm, where D is dosis and AUCra is 
the area under the maternal concentration versus time curve from zero to infinity. 
AUCm was calculated as C0 /a, + Cequim · t120. We assumed that equilibrium was 
reached at 120 min of perfusion since at least 5 times tin were passed. 
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Data are presented as means ± SD, where N is the number of perfusions with 
different placentae. 
Results 
Diffusion properties 
Disappearance from the maternal circulation and concomitant appearance in 
the fetal circulation of the freely diffusionable and practically inert marker 
antipyrine is shown in Figure 2. Almost equal concentrations in both reservoirs 
were reached after 120 min (C
e q u i r a = 35.8 ± 2.4 and Ce q u, r = 33.7 ± 1.6 g/1, N=4). 
Pharmacokinetic analysis of the drug concentration data fitted over 120 min of 
perfusion, revealed a placental antipyrine clearance of 2.33 ± 0.08 ml/min (N=5). 
First order rate constants a, and щ were 0.044 ± 0.006 and 0.034 ± 0.005 min"' 
(N=5) 
Membrane integrity 
In contrast to antipyrine, only 5.7 % of the maternally administered 
concentration of inulin was transferred to the fetal circulation (Fig. 3). 
Approximately 17 % of the maternal concentration of inulin at time zero was 
retained in the perfused cotyledon, together with 6 % transfer to the fetal 
circulation, corresponding to a total disappearance of inulin from the maternal 
circulation of approximately 28 %. 
Metabolic activity 
To determine the metabolic viability of the perfused cotyledon, we 
investigated the glucose utilization and lactate production during 120 min of 
perfusion. Both were linear with time (Fig. 4), the maternal rate being twice the 
fetal rate, corresponding to the higher perfusion rate of the maternal circuit. 
Calculation of the concentrations, corrected for volume loss due to sampling and 
related to the weight of the perfused cotyledon, revealed values of glucose 
consumption and lactate production as mentioned in Table 1. As can be seen, 
lactate production was twice as high as glucose utilization. 
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Table 1. Glucose metabolism in the isolated perfused 
human placental cotyledon 
glucose 
utilization 
lactate 
production 
fetal 
maternal 
0.069 ± 0.040 
0.178 ± 0.043 
0.095 + 0.075 
0.298 ±0.153 
Values are expressed as μπιοΐ/min/g wet weight (mean 
± SD) of 7 perfusions. 
Discussion 
In this study we describe a dual perfusion system of the isolated cotyledon of 
human term placenta. Our goal was to investigate the characteristics in a closed 
circuits model, to validate the system for future placental drug transfer and 
metabolism investigations. This recirculating perfusion method provides a simple 
and physiologically based model for in vivo placental drug transfer. To validate a 
perfusion system one must get insight into the variables that are of influence on 
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transfer processes across the placental barrier. Concentration differences can be 
controlled at the beginning of an experiment, however, for instance membrane 
characteristics are far more difficult to predict. Evaluation of flow-limited, 
membrane limited and metabolic marker compounds can provide more insight into 
the transport characteristics of the perfused cotyledon. 
The rate of disappearance of antipyrine from the perfusion fluid is directly 
proportional to the flow delivering the compound, a mechanism which is called 
flow-dependent transfer (Schneider and Dancis, 1978). In our closed circuits 
perfusion system, maternally administered antipyrine disappeared quickly from the 
maternal compartment with a clearance comparable to literature values (Barzago et 
al., 1994). A concomitant rise into the fetal circulation, reaching equilibrium, was 
observed, although equal concentrations in both circulations were not completely 
reached. This indicates that a very small amount must have been retained in the 
perfused tissue, which was confirmed by the recovery of approximately 4 % of the 
maternally administered antipyrine concentration in the tissue sample (data not 
shown). Furthermore, kinetic analysis of the transfer rates from the maternal into 
the fetal compartment showed that the maternal disappearance rate was faster than 
the fetal appearance rate, possibly reflecting the difference in permeability of both 
sides of the trophoblast (the maternal circulation facing the microvillous membrane 
and the fetal circulation facing the basal membrane). The antipyrine transfer profile 
showed that the maternal and fetal circulations are properly connected and transfer 
from one compartment to the other is possible, without considerable leakage to 
extra-perfused tissue or significant retention into perfused tissue. The permeability 
of the human placenta for inulin, a water-soluble compound with a molecular 
weight of approximately 5500, is much lower than for antipyrine (Challier et al., 
1985a). Indeed, in our experiments, where antipyrine did reach equilibrium at 120 
min, inulin did not, indicating that the placental barrier stayed intact for at least two 
hours. This was also observed in a recirculating perfusion for a period up to six 
hours (Maguire et al., 1992). 
Placental metabolism plays an important role in the transfer of certain 
compounds. For instance, Cortisol is metabolized to cortisone during placental 
transfer (Dancis, 1978) and the lack of transfer of glutamic acid is assumed to be 
due to extensive metabolic degradation to glutamine (Malek et al., 1993). In 
placental fragments a net consumption of glucose and production of lactate and 
ammonia was observed (Holzman et al., 1979). Therefore, glucose utilization and 
lactate production are considered as markers of metabolic viability of the perfused 
cotyledon (Cannell et al., 1988). In our preparation significant glucose utilization 
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and lactate production was observed, maternally higher than fetally, reflecting the 
differences in perfusion rates. The values of this metabolic conversion were 
comparable to those described by Leichtweiss et al. (1985). In the term placenta, 
indeed glucose is mainly metabolized anaerobically, however, since lactate 
production is twice as high as glucose utilization other precursors than glucose must 
be responsible for the lactate production (Challier et al., 1985"). 
In summary, a dual perfusion system of the isolated cotyledon of human 
term placenta has been validated. Maternally administered antipyrine equilibrated in 
both circulations, whereas inulin did not, showing the good diffusibility and 
integrity of the membrane barrier. Since net glucose utilization and lactate 
production was demonstrated, the metabolic viability of the perfused cotyledon was 
preserved. We conclude that our system is suitable for studies on placental drug 
transfer and metabolism. 
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Chapter 8 
CHARACTERISTICS OF SPIRAMYCIN TRANSFER IN THE ISOLATED 
DUALLY PERFUSED COTYLEDON OF HUMAN TERM PLACENTA 
Eric M. van der Aa, Yuen Tan, Jenny H.J. Copius Peereboom-Stegeman' and 
Frans G.M. Rüssel 
Departments of Pharmacology and Toxicology', University of Nijmegen, P.O. Box 
9101, 6500 HB Nijmegen, the Netherlands 
Summary 
The placental transfer of spiramycin was investigated in a dual recirculating 
perfusion system of the isolated cotyledon of human term placenta. Metabolic 
activity, measured as glucose consumption and lactate production, was maintained 
throughout perfusion. Maternal to fetal antipyrine transfer showed a good 
diffusibility of the perfused cotyledon. Spiramycin disappearance from the maternal 
circulation was comparable to antipyrine, indicating passive diffusion into the 
trophoblast. However, in contrast to antipyrine, no concomitant rise in the fetal 
circulation and as a result low trans-placental transfer was observed. An additional 
peak was observed in HPLC chromatograms of perfused tissue and to a lesser 
extent, but gradually increasing, also in maternal perfusate after 60 min of 
perfusion. Placental metabolism is assumed to be the main cause of the observed 
low trans-placental transfer. Due to this low transfer, the therapeutic efficacy of 
spiramycin in fetal Toxoplasma Gondii infection is questioned. Assuming that 
metabolites of spiramycin may be also effective against Toxoplasma Gondii, 
placental spiramycin and metabolites can act as a barrier to placental passage of this 
parasite, resulting in the prevention of fetal infection. 
Introduction 
Primal maternal infections of Toxoplasma Gondii occur in approximately 6-
12 of 1000 human pregnancies, resulting in fetal infections in approximately 40 % 
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of the cases (van der Veen, 1984; Desmonts and Couvreur, 1974). Fetal infections 
during pregnancy by this parasite can cause severe defects, such as microcephalus, 
hydrocephalus or microphtalmia, and even intra-uterine death, spontaneous abortion 
or partus prematurus (Desmonts and Couvreur, 1974). Visus defects and mental 
retardation in later life are also correlated with fetal Toxoplasma Gondii infection 
during pregnancy (Wilson and Remington, 1980). In pregnant women, having 
antibodies due to contact with the parasite before pregnancy, fetal infection is 
assumed to be impossible (Remington and Desmonts, 1990). Because of the severe 
congenitally defects, treatment is essential when infection during pregnancy does 
occur in women devoid of antibodies. The most prescribed treatment in case of 
general Toxoplasma Gondii infection is a combination of pyrimethamine and 
sulfadiazine. However, because of the teratogenic effects of pyrimethamine in rats 
(Horvath et al., 1989), this drug regimen is not the first choice in the treatment of 
fetal infection during pregnancy. 
The macrolide antibiotic spiramycin is bacteriostatic against a variety of 
bacteria and also Toxoplasma Gondii in vitro (Chamberland et al., 1991) and in 
vivo, in mice (Araujo et al., 1991). Since no adverse effects on the fetus are 
observed, spiramycin might be a safe alternative to the usual treatment of 
Toxoplasma Gondii infections during pregnancy. In human, a reduced frequency of 
placental infections was observed when women were treated prophylactically 
(Couvreur et al., 1988). However, whether spiramycin can be also used successfully 
in the treatment of an already infected fetus is unknown. Recently, a limited 
placental transfer of spiramycin was found in rhesus monkey (Schoondermark-van 
de Ven et al., 1994) and human placental cotyledon (Quetin et al., 1983), suggesting 
that fetal therapeutic plasma concentrations will hardly be reached. The in vivo 
prophylactic activity might be explained by the creation of a barrier in the placenta 
to transmisson of the parasite, providing the prevention of trans placental passage 
(Schoondermark-van de Ven et al., 1994). 
The cause of the low trans-placental transfer of spiramycin is unknown. We 
therefore investigated the characteristics of spiramycin transfer in the isolated dually 
perfused cotyledon of human term placenta, to gain insight into the mechanism 
underlying its poor placental permeability. 
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Materials and Methods 
Perfusion system and preparation 
Human term placentae, with clamped umbilical cord, were brought to our 
laboratory in 0.9 % NaCl (4°C), immediately after vaginal or caesarian delivery and 
were cannulated as described in chapter 7. The fetal arterial inflow (37°C) was 
started at 0.15 ml/min and gradually increased to 6 ml/min. Proper connection of 
the fetal artery to the fetal vein was checked by verifying that the fetal venous 
outflow equalled the fetal arterial inflow. The fetally perfused cotyledon was fixed 
in a perspex ring and placed into the perfusion chamber (37°C) with the maternal 
surface faced upwards. Maternal arterial inflow (37 °C) was started by pressing four 
small metal cannulae, gently through the decidual plate, into the intervillous space 
connected to the fetally perfused region. The maternal arterial inflow was gradually 
increased to 12 ml/min. The perfusate returning through the intervillous openings 
was continuously drained. Temperature, pH, and fetal inflow pressure were 
continuously monitored as described in chapter 7. When the volume loss, corrected 
for sampling volume, was more than 3 ml/h the experiment was terminated. Fetal 
inflow pressure was 17 ± 6 mmHg. Since both reservoirs were equilibrated with 
carbogen no net 02 transfer occurs and determination of p02 in these experiments 
was unnecessary. 
Chemicals 
Maternal and fetal perfusates were of the following composition (raM): NaCl 
(112.0), KCl (5.2), NaHC03 (20.2) KH2P04 (0.3), Na2HP04 (0.9), CaCl2 (2.0), 
MgCl2 (1.0), glucose (5.0), to which 2500 IU/1 heparin, 2% bovine serum albumin, 
1% dextran 40 and 1 % Synthamin 14 (a mixture of 15 amino acids) were added. 
The perfusates were equilibrated with 95% 02 and 5% C02 and together with the 
20.2 mM NaHCOj added in the perfusates, pH was buffered to 7.3-7.5. 
Bovine serum albumin Fraction V was obtained from Boehringer Mannheim 
(Mannheim, Germany), heparin (TromboliquinR, 5000 IU/1) was purchased from 
Organon Teknika (Boxtel, the Netherlands) and Synthamin 14 (without electrolytes) 
from Travenol Laboratories Ltd. (Norfolk U.K.). Spiramycin (a complex of 90.0% 
spiramycin I, 0.5% spiramycin II and 6.3% spiramycin III) and spiramycin II were 
kindly provided by Rohne-Poulenc (Alfortville, France). All other chemicals were 
obtained from either Sigma Chemical Co. (St. Louis, U.S.A.) or Merck (Darmstadt, 
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Germany) and were of analytical or HPLC grade. 
Experimental design 
As described in chapter 7, experiments were started in a 30 min single pass 
mode (pre-phase) on both sides to let the cotyledon stabilize and recover from the 
period of anoxia and to clear it from remaining blood. The test-phase of the 
experiment was then started by changing the perfusates and closing the circuits, 
resulting in a recirculating mode of perfusion. The perfusates used in this phase 
(175 ml) were the same as described above, except that spiramycin I (0.88 mg) and 
antipyrine (14.1 mg) were added to the maternal perfusate. 
For determination of spiramycin, antipyrine, glucose and lactate 
concentrations, samples (2 ml) were taken from both reservoirs at every 5 min until 
30 min and at 45, 60, 90, 120 and 180 min and centrifuged (10 min, 1500G) to 
eliminate erythrocytes. Volume loss due to sampling was less than 15 %. After 
termination of the experiment the perfused cotyledon was excised, weighed and 
frozen until analysis. 
Analytical methods 
Antipyrine was measured colorimetrically according to the method described 
by Brodie et al. (1949). Glucose and lactate were measured enzymatically (D-
Glucose-kit; D/L-Lactic acid-kit, Boehringer Mannheim, Germany). Spiramycin was 
measured by HPLC after solid phase extraction of the samples. Samples to which 
spiramycin II was added, as internal standard, were deproteinized with acetonitrile 
and centrifuged (10 min, 2800G). The supernatant diluted with Na2HP04 (0.02 M) 
was brought onto a, with methanol and NajHPC^ (0.02 M) preconditioned, solid 
phase extraction column (Bond Elut, C2, Varían Sample Preparation Products, 
Harbor City, CA, U.S.A.). After washing the column with NajHPO,, (0.02 M) and 
phosphate buffer (0.02 M, pH=3.0), the spiramycin with internal standard were 
eluted from the column with methanol, 0.02 M phosphate buffer, pH=3.0 (65:35 
v/v). The chromatographic system consisted of a Spectra Physics P2000 pump 
(Thermo Separation Products, Breda, the Netherlands), a Lichrospher 60 RP-Select 
В 5 um cartridge column (Merck, 125x4 mm), a cartridge guard column packed 
with the same material (4x4 mm) and an autosampler (Spectra Physics AS 3000) 
with a built in column heater (T = 40°C). The mobile-phase was a methanol-0.02 M 
phosphate buffer, pH=3.0 (39:61 v/v). The flow-rate was 1 ml/min. The column 
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effluent was detected with a Spectra Physics UV 1000 variable wavelength detector 
at 231 nro. The injection volume was 10 ul. 
Data analysis 
Maternal (m) and fetal (f) perfusate concentration-time curves were fitted by 
nonlinear regression analysis using the computer program PCNONLIN (Metzler and 
Weiner, 1989) according to the following equations. 
For antipyrine: 
Cm = ( Ç> ~ Ceçw.m ) ' e + CgçU/m 
Cf-C^r^-e^') 
and for spiramycin: 
Cm = A- '°3'' + В- в ( 
C
m
 and Cf are maternal and fetal perfusate concentrations, C0 is the 
concentration at time zero, a,, o^ and сц are first-order transport rate constants, ß is 
first order elimination rate constant and С ^
 m
 and C ,^,,
 f are the maternal and fetal 
concentrations at equilibrium. Placental clearance (CL) was calculated as D/AUC
m
, 
where D is dose and AUC
m
 is the area under the maternal concentration versus 
time curve from zero to infinity. For antipyrine AUC
m
 is calculated as (ϋ,/α, + 
Chequi' t,2o and for spiramycin as Α/α+Β/β. Half-life of elimination for spiramycin 
was calculated as ln2/ß. 
Data are presented as means ± SD, where N is number of experiments with 
different placentae. 
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Results 
Perfusion viability 
Total (maternal and fetal) glucose consumption was 0.20 ± 0.05 umol/min/g 
wet weight and total lactate production was 0.34 ± 0 . 1 1 umol/min/g wet weight 
(N=3). Mean weight of the perfused cotyledon was 22 ± 7 g (N=3). Disappearance 
from the maternal circulation and concomitant appearance in the fetal circulation of 
the flow-dependent marker antipyrine indicated a good diffusibility of the 
preparation (Figure 1), comparable with literature (Maguire et al., 1992; Barzago et 
al., 1994). Kinetic parameters of antipyrine transfer are presented in Table 1. 
Spiramycin transfer and metabolism 
Figure 1 also shows the placental transfer of maternally administered 
spiramycin. A rapid decrease in the maternal concentration was observed, 
comparable to the antipyrine decrease. However, in contrast to antipyrine, no 
concomitant rise in the fetal circuit was observed. Kinetic parameters of placental 
spiramycin transfer are presented in Table 1. Since no leakage from the perfusion 
system occurred and maternal spiramycin decrease was not accompanied by a 
comparable fetal increase, spiramycin must have been retained in the placenta. At 
the end of the perfusion experiments the concentration of spiramycin detected in the 
perfused tissue was 0.12 pg/ml, which was in the same order as the concentration in 
the fetal circuit (0.28 pg/ml). Both concentrations cannot account for the amount of 
spiramycin that disappeared from the maternal circuit. HPLC chromatograms 
(Figure 2), however, showed an additional, earlier and higher, peak as compared to 
the spiramycin peak in perfused tissue samples. The peak also appeared in the 
maternal perfusate samples at 60 min and increased thereafter. This peak was not 
observed in a standard spiramycin solution maintained at 37°C for two hours, nor in 
samples of the maternal reservoir at t=0 and non-perfused tissue. A spiramycin 
solution in phosphate buffer of pH=3.0 stored at room temperature for several days 
showed a hydrolysis product of spiramycin, known as neospiramycin (Sander and 
Delphine, 1994) with the same retention time as antipyrine (large peak in 
chromatograms С and D in figure 2). Since the retention time of this peak differed 
from the retention time of the additional peak observed in placental tissue and 
maternal perfusate, the metabolite formed during perfusion is not the same as the 
degradation product formed after mild hydrolysis. 
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Figure 1. Time course of antipyrine and spiramycin transfer in the isolated dually recirculating 
perfused cotyledon of human term placenta. Values are presented as means ± SD of three 
experiments for antipyrine. In case of spiramycin a single experiment is shown. 
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Table 1. Kinetic parameters of placental antipynne and spiramycin transfer 
Parameter Antipynne 
N=3 
Co (Mg/ml) 
a, (nun ') 
a ¡ (nun1) 
a, (min ') 
ß (nun1) 
Сщил (Mg/ml) 
AUC (pg-min/ml) 
CL (ml/min) 
t , g e l (min) 
Spiramycin 
N=2 
75 2 ± 6 2 
0043 ± 0008 
0035 ± 0003 
-
. 
38 
-
-
006 
0 005 
35 2 ± 2 7 
33 5 ± 1 6 
6005 ± 177 
2 37 ± 006 
565 
13 
140 
Values are presented as means ± SD or means 
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Figure 2. Chromatograms of perfusate after 30 min of open perfusion (A), perfusate spiked with 
5 3 Mg/ml spiramycin and 6 0 pg/ml internal standard (B), maternal perfusate plus internal standard 
at t=0 (C), maternal perfusate plus internal standard at t=120 nun (D), non-perfused tissue (E) and 
perfused tissue at t=120 mm (F) 1 spiramycin , 2 spiramycin II (internal standard), 3 unknown 
metabolite 
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Discussion 
In this study we evaluated the characteristics of spiramycin transport across 
the human placental cotyledon to get more insight into the mechanisms determining 
its low placental permeability. From in vivo experiments in the rhesus monkey, it 
was concluded that the placenta may act as a clearance organ or a barrier for 
spiramycin, since at three hours after administration the fetal serum concentration 
was only 5-7% of the maternal serum concentration, and the maximal fetal-matemal 
serum ratio was 0.27 (Schoondermark-van de Ven et al., 1994). Furthermore, the 
concentration in the placenta was ten times the concentration in the maternal serum. 
These data corresponded well with a placental transfer rate of approximately 9% of 
maternally circulating spiramycin, which was reported in a preliminary study using 
an open perfusion system of the isolated human placental cotyledon (Quetin et al., 
1983). In an open system, however, only a transfer index in comparison with 
antipyrine can be calculated as a measure of placental transfer. We therefore 
evaluated placental spiramycin transfer in a recirculating perfusion system. This 
system is particularly useful for studying the kinetics of slowly transferred 
compounds and the formation of metabolites by the placenta, which is difficult to 
quantify in a single pass system (Brandes et al., 1983). Since dose-dependent 
kinetics for spiramycin were observed in the rhesus monkey (Schoondermark-van de 
Ven et al., 1994), probably as a result of saturable metabolism, placental 
metabolism may play a role in the low placental transfer. 
In our study trans-placental transfer was also low. The initial disappearance 
rate from the maternal circulation (Oj) was in the same range as the maternal 
disappearance rate of antipyrine (d[). The calculated antipyrine and spiramycin 
clearances were also comparable. Therefore diffusion into the trophoblast seems the 
main transport mechanism governing the disappearance of spiramycin from the 
maternal compartment. Membrane pores are generally too small for passage of a 
relatively large molecule such as spiramycin. Furthermore, the lipophilicity of 
spiramycin is too low to explain transport in the trophoblast by simple diffusion. 
Facilitated diffusion seems to be the most likely mechanism, although we were not 
able to saturate transport in an experiment using a ten times higher concentration of 
spiramycin (data not shown). 
In contrast to antipyrine, spiramycin hardly appeared in the fetal circulation. 
HPLC chromatograms of perfused tissue samples and 60 min matemal perfusate 
samples showed an additional earlier and higher peak as compared to spiramycin. 
The gradual increase in the maternal circuit as the perfusion proceeded suggests that 
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this peak reflects the formation of a metabolite. Spontaneous decomposition of 
spiramycin, explaining the appearance of this peak, is not likely since this peak was 
not found when a spiramycin perfusate solution was kept at 37°C for two hours. It 
could also be excluded that the hydrolysis product, neospiramycin, accounted for 
the unknown peak. The formation of the metabolite, however, does not explain the 
difference between the disappearance of spiramycin from the maternal compartment 
and the small amount that appeared into the fetal compartment. Because no leakage 
was observed from both perfusate reservoirs, other metabolites must have been 
formed, which, due to their presumed hydrophilicity, were not extracted by the solid 
phase procedure we performed to selectively extract spiramycin. That more 
metabolites can be formed out of spiramycin was shown by Inoue et al., (1983) 
after adding rat plasma to a spiramycin standard. Assuming that the metabolites 
may be effective against Toxoplasma Gondii, placental spiramycin and its 
metabolites can act as a barrier to passage of the parasite, providing prevention of 
fetal infection. However, because of the low trans-placental transfer due to placental 
metabolism and the resulting low umbilical cord levels of spiramycin after maternal 
administration, a therapeutic effect of spiramycin against an already present fetal 
infection is not to be expected. 
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Summary and Conclusions 
The placenta is an organ which combines functions performed by separate 
organs in adult life. This feature indicates the extreme importance of the placenta 
for the embryo or fetus in utero. One of the major functions of the placenta is 
absorption of nutrients and excretion of waste products. This transport function of 
the placenta, as an intermediate between fetal and maternal circulation, is mainly 
performed by the syncytial microvillous membrane, facing the maternal blood and 
the basal membrane, facing the fetal blood. Active transport systems in these 
membranes have been found for nutrients, such as amino acids and minerals, 
ensuring an efficient transfer towards the fetus for optimal growth and development. 
Much less is known about the placental handling of drugs taken by the mother and 
the influence of maternally circulating drugs on nutrient transfer towards the fetus. 
Placental drug transport and interactions with nutrients can be of importance to fetal 
development, especially when the mother is obligated to take drugs during 
pregnancy, as for instance in maternal epilepsy, diabetes or hypertension. Because 
of the risks to the fetus it is hardly possible to investigate placental drug transfer in 
human in vivo. Since it has become clear that major interspecies differences exist in 
placental solute transfer, results from animal studies are difficult to extrapolate to 
the human situation. To get more insight into the mechanisms underlying human 
placental drug transfer and the interaction of drugs with nutrient transfer we 
undertook the studies described in this thesis. Two experimental models were used: 
1. Syncytial microvillous membrane vesicles isolated from human term placenta. 
This technique provides information especially on the mechanisms of drug 
transport and drug-nutrient interactions, e.g. driving forces, type of transport 
and the kinetics of saturation and interaction with structural analogs. 
2. The isolated dually perfused cotyledon of human term placenta. This 
physiologically based model can provide more insight into the overall placental 
drug transfer. Furthermore, the influence of placental metabolism on drug 
transfer can be evaluated. 
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This thesis is divided into three parts: 
I Introduction, in which relevant literature data on human placental drug transfer 
mechanisms are reviewed. 
II Studies on mechanisms of transport and interactions with nutrients of anionic 
and cationic drugs in isolated syncytial microvillous membrane vesicles, p-
Aminohippurate, commonly used in renal studies, was chosen as a prototypic 
anionic compound and the H2-receptor antagonist Cimetidine as a cationic 
model compound. Furthermore, the inhibitory effects of various anionic and 
cationic drugs on the transport of the amino acid L-alanine and the endogenous 
organic cation choline were investigated. 
III Studies on overall human placental drug transfer and metabolism in the isolated 
dually perfused cotyledon of human term placenta. The macrolide antibiotic 
spiramycin was investigated. 
I Introduction 
In chapter 1 we summarized the literature on human placental drug transfer 
mechanisms. Active drug transport mechanisms have been rarely found in cotyledon 
perfusion and vesicle studies. The amount or rate of transfer was mainly determined 
by the physico-chemical characteristics of the drug, such as molecular weight, 
lipophilicity, degree of ionisation at physiological pH and degree of protein binding 
and by physiological factors, such as maternal blood flow rate and placental 
metabolism. In most cases overall placental drug transport appears to be governed 
by simple diffusion, however, in some cases membrane transport was saturable. 
Especially the transport of some drugs structurally related to endogenous 
compounds was found to be carrier mediated. In conclusion, membranes of human 
term placenta possess carrier systems having affinity for certain drugs, however, in 
general overall human placental drug transfer will be passive. 
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Π Drug transport and interactions in isolated membrane vesicles 
In chapter 2 an improved method is described for the isolation of syncytial 
microvillous membrane vesicles from human term placenta according to an 
established procedure. The method is based on mincing and gently stirring of 
placental tissue to loosen the microvilli, followed by Mg2+-aggregation and 
harvesting of the syncytial microvillous membrane vesicles by differential 
centrifugation. The vesicle preparation showed a high degree of purification, high 
yield and good functional viability. Uptake of the amino acid L-alanine was 
sodium-dependent, saturable (1^= 230 μΜ) and susceptible to inhibition by 
structural analogs. However, significant interactions with anionic or cationic drugs, 
catecholamines and certain drugs of abuse with the alanine transporter were not 
found. On the other hand, a number of cationic drags significantly inhibited the 
uptake of the endogenous cation choline. 
In chapter 3 the mechanism of uptake of the organic anion p-aminohippurate 
into syncytial microvillous membrane vesicles was investigated. Uptake was pH-
and Cl-dependent, whereas a forced negative or positive membrane potential did 
not influence p-aminohippurate uptake. Since an anion exchange mechanism was 
also excluded, no driving forces seem to be present for p-aminohippurate in these 
membranes. However, evidence for the existence of a carrier-mediated transport 
mechanism was obtained since uptake was inhibited by several anionic drags Ce.g. 
K,
 p r o b c n e c i d= 2.5 mM) and saturable (1^= 7.4 raM). The significance of this system 
for placental excretion of anionic drugs is difficult to value from these experiments, 
but will depend on the intrasyncytial drug concentration achieved through transport 
from the fetal circulation across the basal membrane. 
The presence of a mediated transport mechanism for cationic drugs in these 
vesicles was investigated in chapter 4. Uptake of the cationic H2-receptor antagonist 
Cimetidine was stimulated by the imposition of an outwardly directed H+-gradient 
(peak vs. equilibrium = 1.3). The peak uptake was decreased under voltage clamped 
conditions by the proton-ionophore FCCP, suggesting the presence of an organic 
cation-proton exchange mechanism. H+-gradient driven Cimetidine uptake was partly 
inhibited by structural analogs and saturable (K
m
=6.5 mM). Although our results 
provide evidence for the presence of an active transport mechanism for Cimetidine, 
the main part of transport occurred by simple diffusion. The barrier function of the 
human placenta to Cimetidine transport as described in literature, is not likely to be 
caused by an active transport system. The degree of ionization of Cimetidine at 
physiological pH seems to be a more plausible explanation. 
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In chapters 5 and 6 the uptake mechanism of the endogenous cation choline and 
the nature of interaction with various cationic drugs were investigated. An inside 
negative membrane potential and an inside-out choline-gradient stimulated choline 
uptake (peak vs. equilibrium = 1 . 8 and 2.1, respectively). Trans-stimulated uptake 
was saturable (1^= 550 uM). As the maternal blood concentration of choline is 
approximately 20 μΜ, the system assures an efficient placental uptake from 
maternal blood driven by the negative cell interior. Several organic cations inhibited 
trans-stimulated choline uptake: hemicholinium-3 > atropine > choline > mepiper-
phenidol > Cimetidine > famotidine > tetraethylammonium. TEA was a poor 
inhibitor, but by enlarging the degree of alkylation of the quaternary ammonium the 
inhibitory effect was increased. Hemicholinium-3 and atropine inhibited choline 
uptake competitively (K¡ = 40 μΜ and 1.2 mM, respectively), whereas Cimetidine 
interacted noncompetitively (K¡ = 3.4 mM). Since relatively high concentrations 
were needed to reach half maximal inhibition, impairment of fetal choline supply 
due to maternal drug use during pregnancy is not to be expected. 
Ill Drug transfer across the isolated dually perfused cotyledon 
Chapter 7 deals with the validation of a dual perfusion system of the isolated 
cotyledon of human term placenta. The recirculating (closed) perfusion system 
showed a good diffusibility, since the disappearance of antipyrine from the maternal 
circulation (clearance = 2.33 ml/min) and concomitant rise in the fetal circulation, 
was comparable to literature. In contrast with antipyrine, the hydrophilic, membrane 
impermeable compound inulin crossed the placenta for only approximately 6 %, 
indicating the integrity of the membrane barrier. Metabolic viability of the 
preparation was preserved, since a net glucose/lactate conversion was found. We 
conclude that our system is suitable for placental drug transfer and metabolism 
studies. 
In chapter 8 we investigated the mechanism underlying the low transfer of the 
macrolide antibiotic spiramycin across the human placenta, as described in 
literature. The recirculating dual perfusion system of the isolated human placental 
cotyledon was used. Spiramycin disappearance from the maternal circulation was 
comparable to antipyrine, indicating passive diffusion into the trophoblast. However, 
in contrast with antipyrine, no concomitant rise in the fetal circulation and as a 
result low trans-placental transfer was observed. Spiramycin did not accumulate in 
placental tissue, but an additional peak was observed in HPLC chromatograms of 
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perfused tissue and to a lesser extent, but gradually increasing, also in the maternal 
perfusate. It seems that placental metabolism is assumed to be the main cause in the 
observed low placental transfer. 
In conclusion, the studies described in this thesis have shown that mediated 
transport systems for anionic and cationic drugs are present in the syncytial 
microvillous membrane of human term placenta. However, their affinity and 
specificity appear to be low. Transport systems for the endogenous compounds 
alanine and choline are relatively insensitive to interaction with drugs. Important 
factors influencing fetal drug exposure are those that can change equilibrium of 
unbound drug between maternal and umbilical cord blood, viz. pH differences, 
differential protein binding, fetal and maternal drug elimination or placental 
metabolism, as was hypothesized in this thesis for spiramycin. Therefore, the results 
derived from the studies described in this thesis justify the conclusion that placental 
active drug transport mechanisms are of minor importance in fetal drug exposure. 

Samenvatting en Conclusies 
De placenta is een orgaan dat zorg draagt voor functies die na de geboorte door 
verschillende organen worden uitgevoerd. Dit betekent dat de placenta van groot 
belang is voor de zich ontwikkelende foetus. Een van de belangrijkste functies is de 
aanvoer van voedingstoffen naar de foetus en afvoer van afvalprodukten van de 
foetus naar de moeder. Deze transportfunctie van de placenta, als intermediair 
tussen de foetale en maternale bloedcirculaties, wordt met name vervuld door de 
syncytiale microvilleuze membraan, die in contact staat met het maternale bloed en 
de basale membraan, welke grenst aan het foetale bloed. Actief transport over deze 
membranen is aangetoond voor nutriënten, zoals aminozuren en mineralen, 
waardoor een efficiënte aanvoer van voedingsstoffen naar de foetus voor optimale 
groei en ontwikkeling is gewaarborgd. Veel minder is bekend over de placentaire 
transportkarakteristieken van geneesmiddelen door de moeder gebruikt tijdens de 
zwangerschap en de invloed die geneesmiddelen in het maternale bloed kunnen 
hebben op het transport van nutriënten naar de foetus. Placentair 
geneesmiddeltransport en interacties met nutriënten kunnen van invloed zijn op 
groei en ontwikkeling van de foetus, in het bijzonder wanneer de moeder tijdens 
haar zwangerschap niet buiten geneesmiddelen kan, zoals het geval is bij epilepsie, 
hypertensie of diabetes. Vanwege de risico's voor de foetus is het nagenoeg 
onmogelijk om het transport van geneesmiddelen door de humane placenta in vivo 
te bestuderen. Uit diverse onderzoeken is duidelijk geworden dat er belangrijke 
speciësverschillen bestaan in placentaire transportkarakteristieken. Daarom kunnen 
de resultaten van proefdier- onderzoek moeilijk geëxtrapoleerd worden naar de 
situatie in de mens. Om meer inzicht te verkrijgen in transportmechanismen van 
geneesmiddelen door de humane placenta en de mogelijke interacties met het 
placentaire transport van nutriënten, is het onderzoek opgezet en uitgevoerd waarvan 
de resultaten zijn beschreven in dit proefschrift. Voor het onderzoek is gebruik 
gemaakt van twee modellen: 
1. Syncytiale microvilleuze membraanvesicles geïsoleerd uit de humane placenta a 
term. Deze techniek maakt het mogelijk om de mechanismen van 
geneesmiddeltransport en interacties met nutriënten te bestuderen, zoals 
drijvende krachten, aard van het transport, kinetiek van verzadiging en 
interacties met structuuranalogen. 
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2. Het geïsoleerde tweezijdig-geperfundeerde cotyledon van de humane placenta a 
terra. Deze meer fysiologische techniek maakt het mogelijk om het totale 
transport van geneesmiddelen over de placenta te bestuderen, waarbij ook de 
invloed van metabolisme op het geneesmiddeltransport kan worden onderzocht. 
Het proefschrift is opgebouwd uit drie delen: 
I Een inleiding waarin de relevante literatuur over mechanismen van 
geneesmiddeltransport in de humane placenta wordt besproken. 
II Studies naar de mechanismen van transport en interacties met nutriënten van 
anionische en kationische geneesmiddelen. Het in niertransportstudies veel 
gebruikte para-aminohippuraat werd gekozen als modelverbinding voor de 
anionische farmaca en de H2-receptorantagonist Cimetidine voor de kationische 
farmaca. In dit deel is ook onderzoek gedaan naar de invloed van diverse 
anionische en kationische geneesmiddelen op het transport van het aminozuur 
L-alanine en het endogene kation choline. 
ΙΠ Studies betreffende het transport en metabolisme van geneesmiddelen in het 
geïsoleerde tweezijdig-geperfundeerde cotyledon van de humane placenta a 
term. In deze studies stond het macrolide antibioticum spiramycine centraal. 
I Inleiding 
In hoofdstuk 1 is de literatuur betreffende transport van geneesmiddelen in de 
humane placenta samengevat. Actieve transportmechanismen zijn slechts een enkele 
keer gevonden in cotyledon-perfusiestudies en vesicle-studies. Over het algemeen 
wordt de mate van transport bepaald door de fysisch-chemische eigenschappen van 
de stof, zoals molekuulgewicht, lipofiliteit, mate van ionisatie bij fysiologische pH 
en mate van eiwitbinding en door fysiologische factoren zoals maternale 
bloedstroom of placentair metabolisme. In de meeste gevallen verloopt het totale 
placentaire transport via passieve diffusie, echter in enkele gevallen bleek dat de 
membraanpassage verzadigbaar was. Dit gold voor farmaca die qua structuur lijken 
op endogene verbindingen. Dit betekent dat de membranen van de humane placenta 
carriersystemen bezitten die affiniteit vertonen voor bepaalde geneesmiddelen, maar 
dat het totale placentaire transport in de regel passief verloopt. 
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II Geneesmiddeltransport en interacties in geïsoleerde membraanvesicles 
In hoofdstuk 2 wordt de methode beschreven voor isolatie van syncytiale 
microvilleuze membraanvesicles uit de humane placenta a term, volgens een reeds 
eerder beschreven maar door ons verbeterde procedure. De methode is gebaseerd op 
het fijnhakken en vervolgens voorzichtig roeren van placentaweefsel, waardoor de 
microvilli los komen van de rest van het weefsel. Hierna worden met behulp van 
Mg2+-aggregatie en differentiële centrifugatie de syncytiale microvilleuze 
membraanvesicles geïsoleerd. Het preparaat vertoonde een hoge zuiverheidsgraad, 
opbrengst en goede functionele eigenschappen. De opname van het aminozuur L-
alanine was natrium-afhankelijk, verzadigbaar (Κ„= 230 μΜ) en te remmen met 
structuuranaloga. Diverse anionische en kationische farmaca, catecholamines en 
bepaalde verslavende middelen gaven geen interactie met het alaninetransport. 
Daarentegen werd het transport van choline wel geremd door een aantal kationische 
farmaca. 
In hoofdstuk 3 wordt het onderzoek beschreven naar de transportmechanismen 
van het organisch anion p-aminohippuraat in syncytiale microvilleuze 
membraanvesicles. De opname was afhankelijk van de pH en van de aanwezigheid 
van chloride. Het aanleggen van verschillende membraanpotentialen had echter 
geen effect op de opname. Omdat eveneens een anion-exchange-mechanisme niet 
werd gevonden, is het waarschijnlijk dat er geen directe drijvende kracht voor de 
opname van p-aminohippuraat in deze vesicles bestaat. Er werd echter wel een 
aanwijzing gevonden voor de aanwezigheid van een carriersysteem, omdat de 
opname te remmen was met structuuranaloga (bijv. K,
-probenKld= 2.5 mM) en 
verzadigbaar was (K
m
= 7.4 mM). De bijdrage van dit systeem aan de eventuele 
placentaire excretie van anionische farmaca in vivo zal afhangen van de 
opgebouwde intrasycyntiale concentratie van deze stoffen als gevolg van transport 
over de basale membraan. 
De eventuele aanwezigheid van gemedieerd transport voor kationische farmaca 
in deze membranen is onderzocht zoals beschreven in hoofdstuk 4. De opname van 
de kationische H2-receptorantagonist Cimetidine werd gestimuleerd door een 
uitwaards-gerichte H+-gradient (piekopname versus evenwichtswaarde = 1.3). De 
piekopname werd verlaagd door de proton-ionofoor FCCP onder condities waarbij 
de membraanpotentiaal geen rol speelde. Dit is een aanwijzing voor een 
mechanisme dat organische kationen tegen protonen kan uitwisselen. De H+-
gradient-gestimuleerde Cimetidine opname werd gedeeltelijk geremd door structuur­
analoga en was verzadigbaar (K„=6.5 mM). Ondanks dat deze resultaten bewijs 
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leveren voor de aanwezigheid van een actief transport-mechanisme voor Cimetidine, 
bestond het grootste deel van het transport uit passieve diffusie. De in de literatuur 
beschreven barrière van de placenta voor Cimetidine kan dan ook niet worden 
toegeschreven aan de activiteit van een dergelijk mechanisme, maar veeleer aan de 
relatief hoge ionisatiegraad van Cimetidine bij fysiologische pH. 
In de hoofdstukken 5 en 6 is het onderzoek beschreven naar het mechanisme 
van transport van het endogene kation choline en de interactie met verscheidene 
organische kationen in syncytiale microvilleuze membraanvesicles. Een negatieve 
membraanpotentiaal aan de binnenkant van de membraan en een uitwaardse 
choline-gradient stimuleerden de opname van choline (piekopname versus 
evenwichtswaarde waren respectivelijk 1.8 en 2.1). De trans-gestimuleerde opname 
was verzadigbaar (Km= 550 μΜ). Omdat de maternale bloedconcentratie van choline 
ongeveer 20 uM is, is in vivo een efficiënte placentaire cholineopname via dit 
systeem verzekerd. Verscheidene organische kationen waren in staat het trans-
gestimuleerde transport van choline te remmen: hemicholinium-3 > atropine > 
choline > mepiperphenidol > Cimetidine > famotidine > tetraethylammonium. 
Hemicholinium-3 en atropine remden de choline-opname competitief (K, 
respectievelijk 40 μΜ en 1.2 mM), terwijl Cimetidine een noncompetitieve interactie 
liet zien (K, = 3.4 mM). Omdat relatief hoge concentraties nodig waren om half-
maximale inhibitie te bewerkstelligen, zal een nadelige invloed van dergelijke 
farmaca op de placentaire cholineopname in vivo niet te verwachten zijn. 
III Geneesmiddeltransport in het geïsoleerde tweezijdig-geperfundeerde 
cotyledon 
Hoofdstuk 7 behandelt de validatie van het geïsoleerde tweezijdig-
geperfundeerde cotyledon van de human placenta a term. Het recirculerende 
(gesloten) perfusiesysteem liet een goede diffusie van antipyrine zien, omdat de 
verdwijning uit de maternale circulatie (klaring = 2.33 ml/min) en de gelijktijdige 
verschijning in de foetale circulatie goed overeen kwamen met data uit de literatuur. 
In tegenstelling tot antipyrine passeerde het hydrofiele, membraanondoorgankelijke 
inuline het cotyledon voor slechts ongeveer 6 %, hetgeen een indicatie vormt voor 
de intactheid van de placentabarrière. De metabole activiteit van het preparaat is 
eveneens goed bewaard gebleven, omdat een netto glucose/lactaat omzetting kon 
worden aangetoond. Op basis van deze gegevens hebben we geconcludeerd dat ons 
systeem geschikt is voor het doen van studies naar placentaire passage en 
metabolisme van geneesmiddelen. 
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In hoofdstuk 8 is het onderzoek beschreven naar het onderliggende mechanisme 
van het lage trans-placentaire transport van het macrolide antibioticum spiramycine, 
zoals in de literatuur is gerapporteerd. Er is gebruik gemaakt van het hierboven 
beschreven perfusiesysteem van het cotyledon uit de humane placenta a term. De 
verdwijning van spiramycine uit de matemale circulatie was vergelijkbaar met die 
van antipyrine, hetgeen een aanwijzing vormt voor passief transport de placenta in. 
Echter, in tegenstelling tot antipyrine werd de maternale verdwijning van 
spiramycine niet gevolgd door een gelijktijdige foetale verschijning, waardoor netto 
een lage transplacentaire passage werd gevonden. Spiramycine accumuleerde niet in 
de placenta, maar op HPLC-chromatogrammen van monsters van geperfundeerd 
weefsel werd een additionele piek gevonden, die eveneens - maar in mindere mate 
en geleidelijk in hoogte stijgend - ook in monsters van het maternale perfusaat 
vanaf 60 min werd waargenomen. Deze piek geeft aan dat placentair metabolisme 
waarschijnlijk als oorzaak van het waargenomen lage trans-placentaire transport van 
spiramycine kan worden aangemerkt. 
Geconcludeerd kan worden dat de studies zoals beschreven in dit proefschrift 
aangeven dat gemediëerd transport van anionische en kationische farmaca aanwezig 
is in de syncytiale microvilleuze membraan van de humane placenta a term, maar 
dat er sprake is van een lage affiniteit en lage specificiteit van de systemen. De 
actieve transportsystemen voor de endogene verbindingen alanine en choline blijken 
relatief ongevoelig te zijn voor remming met anionische en/of kationische farmaca. 
De belangrijkste factoren die de foetale blootstelling aan geneesmiddelen kunnen 
beïnvloeden zijn die welke het evenwicht van het vrije farmacon tussen het 
maternale en navelstrengbloed bepalen, zoals pH-verschillen, verschillen in eiwit-
binding, maternale en foetale eliminatie of placentair metabolisme, zoals is 
gevonden voor spiramycine. Daarom rechtvaardigen de resultaten beschreven in dit 
proefschrift de conclusie dat actieve transportmechanismen voor geneesmiddelen in 
de placenta een ondergeschikte rol spelen bij de expositie van farmaca aan de 
foetus. 
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beloven dat we samen gaan genieten van wat de naaste toekomst ons zal gaan 
brengen. 
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STELLINGEN 
Behorende bij het proefschrift 
Drug transport and drug-nutrient interactions in the human placenta 
E M van der Aa, 15 november 1995 
1 Het transport van geneesmiddelen door de humane placenta wordt in de regel bepaald door 
diffusie 
dit proefschrift 
2 Bij de beschrijving van het placentaire transport van geneesmiddelen is het begnp 'zeef' 
een betere benaming voor de humane placenta dan het begrip 'barrière' 
Prof Dr CAM van Cinneken, 1989 
3 De transportmechanismen van organische amonen en kationen over de microvilleuze 
membraan van de humane placenta komen niet overeen met de mechanismen die 
beschreven zijn voor de brush-border en basolaterale membraan van de mertubulus 
dit proefschrift 
4 De cholme-carrier in de microvilleuze membraan van de humane placenta verzekert een 
efficiente foetale chohnevoorziening 
dit proefschrift 
5 In tegenstelling tot wat soms in de literatuur wordt verondersteld, betekent interactie van 
een geneesmiddel met een transporteiwit nog niet dat het eiwit het geneesmiddel ook 
daadwerkelijk transporteert 
6 Niet alleen een diepgevroren moederkoek kan nog heel wat opleveren 
de Volkskrant. 9 februari 1993 
7 De op een stoplicht gelijkende kleurverandering van de humane placenta van rood naar 
groen, die kan optreden bij meconiumhoudend vruchtwater, is niet indicatief voor een 
mogelijke transportregulerende functie van de placenta 
eigen waarneming 
8 Stageprojecten voor studenten, als onderdeel van promotieonderzoek dat gebruik maakt van 
organen van het vrouwelijk lichaam, wekken vooral interesse bij de vrouwelijke 
studentenpopulatie 
9 Het vóórkomen van de humane placenta op de menukaart van een restaurant in Wusban 
(Centraal China) kan de wetenschappelijke vooruitgang van chinees placentaonderzoek 
ernstig schaden 
de Gelderlander, 15 januari 1994 
10 Farmacolherapie-beleid in Nederland dreigt een aangelegenheid te worden van de 
zorgverzekeraars in plaats van de daarvoor terdege opgeleide beroepsgroepen van apotheker 
en arts 



